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Implementing Botwana's National Cervical Cancer Prevention Programme:
Providers' Fidelity To The See-And-Treat Algorithms
Abstract
Precancerous cervical lesions can be easily prevented and treated. Yet, cervical cancer remains the most
commonly diagnosed cancer and leading cause of cancer-related deaths for women in Botswana. To
address this high burden, Botswana’s Ministry of Health (MOH) established the National Cervical Cancer
Prevention Programme (NCCPP), which primarily focused on secondary prevention using the evidencebased, see-and-treat approach. See-and-treat is an alternative to Pap smear that combines screening
(visual inspection with acetic acid, VIA) and treatment (cryotherapy) in a single visit approach. After
successful pilot testing in the capital city of Gaborone, the program was scaled-up in 2014 to 5 additional
sites (Lobatse, Selebi-Phikwe, Maun, Francistown, and Mahalapye).
To achieve population-level reductions in cervical cancer, the goal of scale-up is to implement health
innovations with high fidelity and achieve desired coverage. Therefore, the overarching goal of this
dissertation was to comprehensively assess providers’ fidelity during scale-up of see-and-treat in
Botswana. Fidelity was composed of two key aspects: (1) adherence, how well nurses’ treatment and
referral choices aligned with the NCCPP see-and-treat algorithm and (2) competence, the level of skill
maintained when nurses performed VIA screenings.
Despite significant barriers to practice, results from this dissertation suggest that Botswana’s MOH
accomplished a successful scale-up. Adherence was maintained during scale-up and competence was
sustained over time. When controlling for covariates using log-binomial regression, adherence did not
differ significantly between pilot and scaled-up sites (p=.2205). In addition, nurses at the pilot site
achieved 75.4% sensitivity and 92.4% specificity when comparing their performance in conducting VIA to
that of expert physicians, which was comparable to estimates attained in the pilot test. The quantitative
data collected in this study has helped to identify problematic segments of the NCCPP see-and-treat
algorithm. Future qualitative interviews will further elicit how and why providers experience
implementation challenges in their daily practice and the implications for program fidelity. Botswana and
other resource-limited countries can utilize these results to modify the see-and-treat algorithm, develop a
fidelity instrument to facilitate ongoing monitoring, and/or test strategies to improve the scale-up process
moving forward.
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ABSTRACT
IMPLEMENTING BOTSWANA’S NATIONAL CERVICAL CANCER PREVENTION
PROGRAMME: PROVIDERS’ FIDELITY TO THE SEE-AND-TREAT
ALGORITHMS
Lauren G. Johnson
Alison M. Buttenheim, PhD, MBA
Precancerous cervical lesions can be easily prevented and treated. Yet, cervical
cancer remains the most commonly diagnosed cancer and leading cause of cancer-related
deaths for women in Botswana. To address this high burden, Botswana’s Ministry of
Health (MOH) established the National Cervical Cancer Prevention Programme
(NCCPP), which primarily focused on secondary prevention using the evidence-based,
see-and-treat approach. See-and-treat is an alternative to Pap smear that combines
screening (visual inspection with acetic acid; VIA) and treatment (cryotherapy) in a
single visit approach. After successful pilot testing in the capital city of Gaborone, the
program was scaled-up in 2014 to 5 additional sites (Lobatse, Selebi-Phikwe, Maun,
Francistown, and Mahalapye).
To achieve population-level reductions in cervical cancer, the goal of scale-up is
to implement health innovations with high fidelity and achieve desired coverage.
Therefore, the overarching goal of this dissertation was to comprehensively assess
providers’ fidelity during scale-up of see-and-treat in Botswana. Fidelity was composed
of two key aspects: (1) adherence, how well nurses’ treatment and referral choices
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aligned with the NCCPP see-and-treat algorithm and (2) competence, the level of skill
maintained when nurses performed VIA screenings compared to expert physicians.
Despite significant barriers to practice, results from this dissertation suggest that
Botswana’s MOH accomplished a successful scale-up. Adherence was maintained
during scale-up and competence was sustained over time. When controlling for
covariates using log-binomial regression, adherence did not differ significantly between
pilot and scaled-up sites (p=.2205). In addition, nurses at the pilot site achieved 75.4%
sensitivity and 92.4% specificity when comparing their performance in conducting VIA
to that of expert physicians, which was comparable to estimates attained in the pilot test.
The quantitative data collected in this study has helped to identify problematic segments
of the NCCPP see-and-treat algorithm. Future qualitative interviews will further elicit
how and why providers experience implementation challenges in their daily practice and
the implications for program fidelity. Botswana and other resource-limited countries can
utilize these results to modify the see-and-treat algorithm, develop a fidelity instrument to
facilitate ongoing monitoring, and/or test strategies to improve the scale-up process
moving forward.
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CHAPTER 1: Introduction to the body of work
Overview
Cervical cancer is a high-burden global health concern with 528,000 new cases
and 266,000 deaths estimated in 2012 for women worldwide (GLOBOCAN, 2012).
Much of this global burden (approximately 85%) lies in less developed countries, with
regions in sub-Saharan Africa (SSA) having the largest age-standardized incidence and
mortality rates (GLOBOCAN, 2012; De Vuyst et al., 2013). Developed countries, such
as the United States, have achieved significant decreases in cervical cancer since the
wide-scale roll out of Pap smear in the 1960s. However, many countries in SSA have not
been able to attain such reductions due to implementation barriers and resource
limitations (Chidyaonga-Maseko, Chirwa, & Muula, 2015; Denny, Quinn, &
Sankaranarayanan, 2006; Jemal et al., 2012; Lim & Ojo, 2017; McFarland, Gueldner, &
Mogobe, 2016; Randall & Ghebre, 2016; Safaeian, Solomon, & Castle, 2007).
Scale-up of health innovations that attain broad coverage is needed to achieve
population-level reductions in disease burden (Fixsen, Lundgren, Igras, Jennings, &
Sinai, 2013; Milat, Bauman, & Redman, 2015). Therefore, the challenge of implementing
and adequately sustaining Pap smear programs has initiated the search for alternative
methods of screening more appropriate for low-resource settings (Sankaranarayanan,
Anorlu, Sangwa-Lugoma, & Denny, 2013). See-and-treat is one of the innovative
approaches that was developed, which combines visual inspection with acetic acid (VIA)
– a simplified procedure performed by nurses to identify precancerous lesions on the
cervix – with immediate cryotherapy treatment (Ramogola-Masire et al., 2012; T. C.
Wright Jr & Kuhn, 2012). In theory, see-and-treat is intended to address the
1

shortcomings of Pap-smear programs by being more cost-effective, addressing physician
shortages by task sharing with nurses, and reducing loss to follow-up with a single-visit
approach. While improvements have been made, scale-up remains challenging.
Countries that have implemented see-and-treat faced barriers such as: inadequate water
and electricity supply, lack of equipment and supplies, equipment malfunction and repair
needs, budget restraints, staff retention and heavy workload, competing priorities, and
lack of supervision (Martin et al., 2014; Munthali, Ngwira, & Taulo, 2015; Shiferaw et
al., 2016).
Although the necessary knowledge and tools to prevent cervical cancer exist, a
significant research-to-practice gap has hindered many women from receiving these
preventive services (Maseko, Chirwa, & Muula, 2015; McCree et al., 2015; Randall &
Ghebre, 2016). Within the field, the status quo has been to develop new screening
techniques to circumvent the implementation barriers of low resource settings
(Sankaranarayanan et al., 2013). However, as exemplified with Pap smear and the seeand-treat approach, these challenges continue to impede scale-up of cervical cancer
prevention programming. Arguably, more resources are duplicated or wasted in the
process of prematurely implementing an innovation rather than thoroughly assessing how
and why the previous technique was not as successful as anticipated. When desired
health outcomes are not achieved after an evidence-based program is implemented, the
failure is typically attributed to the program or screening technology without
consideration of how well it was or was not implemented in that particular setting
(Brownson, Colditz, & Proctor, 2012).
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Using an implementation science perspective, this dissertation calls for a
paradigm shift. In addition to developing new prevention tools, it is important to
explicitly and rigorously examine the implementation of cervical cancer prevention
programs in SSA. Few studies have sought to: (1) better understand the contexts in
which cervical cancer screening programs work best and for whom and (2) identify
strategies that can be used to improve the scale-up process. This dissertation seeks to
help fill the identified literature gap, using Botswana as a case example. Botswana has
recently completed the final year of its 2012-2016 National Cervical Cancer Prevention
Programme (NCCPP), which primarily focused on secondary prevention and scale-up of
the see-and-treat approach. This is an optimal time to evaluate NCCPP and provide the
Ministry of Health (MOH) with insights about implementation, especially since the MOH
is preparing to add HPV vaccination and HPV self-sampling to an already complex
modality of screening and treatment (Botswana MOH, 2011).
Specific Aims
Precancerous cervical lesions can be easily prevented and treated (Denny &
Wright, 2009; Fiander, 2011). Yet, cervical cancer remains the most commonly
diagnosed cancer and leading cause of cancer-related deaths among women in Botswana
(GLOBOCAN, 2012).
Botswana’s MOH has identified cervical cancer as a priority disease target and
made substantial, coordinated investments in prevention, screening, and treatment
services around the country through the NCCPP (Botswana MOH, 2011). A primary
focus of NCCPP is secondary prevention and the scale-up of an evidence-based, see-andtreat algorithm (see Figure 1.1). See-and-treat has proven safe, effective, and feasible in
3

the initial Gaborone pilot test and other cited efficacy and effectiveness trials within the
literature (Chung et al., 2013; Consul et al., 2012; Fokom-Domgue et al., 2015; Nooh,
Mohamed, & El-Alfy, 2015; Ramogola-Masire et al., 2012). However, the proven
effectiveness demonstrated in the trials will not translate into practice if fidelity is not
maximized in implementing NCCPP (Breitenstein et al., 2010; Carroll et al., 2007).
Fidelity is an implementation outcome used to indicate “the degree to which a
practice or intervention is implemented as originally prescribed in the protocol or as
intended by the program developers” (Breitenstein et al., 2010; Gaddis, Greenwald, &
Huckson, 2007). Fidelity provides increased confidence that the program will yield its
intended outcomes. It is composed of two key aspects: (1) adherence, the degree to
which essential program elements are implemented and (2) competence, the level of skill
maintained throughout the implementation process (Breitenstein et al., 2010; Carroll et
al., 2007). This dissertation seeks to comprehensively assess providers’ fidelity to the
NCCPP see-and-treat algorithm in Botswana with following specific aims:
Aim 1. To determine nurses’ adherence to the NCCPP see-and-treat algorithm
Aim 2. To compare nurses’ adherence between the pilot site and scaled up sites
Hypothesis: Adherence to see-and-treat algorithm will be significantly
higher at the pilot site compared with the scaled-up sites
Aim 3. To explore reasons why pilot and scaled-up sites differ in adherence rates
Aim 4. To compare nurses’ competency in performing VIA to their physician
colleagues as the gold standard.
Background and Significance

4

Cervical Cancer Prevention
The burden of cervical cancer is high. The International Agency for Research on
Cancer (IARC) estimated 528,000 new cases and 266,000 deaths from cervical cancer in
2012 for women worldwide (GLOBOCAN, 2012). Sub-Saharan Africa is a high-risk
region with rates only expected to continue rising (De Vuyst et al., 2013). As one of the
countries in this region, Botswana is no exception to the overall trends. Cervical cancer is
the most commonly diagnosed for Batswana women, composing 29% of all female
cancers (GLOBOCAN, 2012). This rate is nearly twofold that of breast cancer (18%).
Cervical cancer is also the leading cause of female cancer-related deaths (23.1%),
followed by breast cancer at 12.5%. If current trends persist, cervical cancer rates in
Botswana are projected to increase by approximately 40% by 2035 (GLOBOCAN,
2012).
Prevention is key to decreasing burden. With adequate resources, cervical cancer
can be easily prevented (Denny & Wright, 2009; Fiander, 2011). The incubation period
between HPV infections potentially developing into cervical cancer is 10 to 20 years,
allowing ample opportunity to screen, track, and halt disease progression ("Cancers of
the female reproductive organs," 2014). Furthermore, there are numerous technologies
that have been proven safe and effective for detecting and treating lesions including Pap
smear, colposcopy, visual inspection with acetic acid or Lugol’s iodine (VIA/VILI), HPV
DNA testing, cone biopsy, cryotherapy, and loop electrosurgical incision procedure
(LEEP) (Mishra, Pimple, & Shastri, 2011; Safaeian et al., 2007).
However, scale-up of these technologies is particularly challenging in resourcelimited settings (Maseko et al., 2015; McCree et al., 2015; Randall & Ghebre, 2016).
5

Pap smear has been the standard screening protocol in developed countries for decades
and caused significant decreases in burden (Jemal et al., 2012; Safaeian et al., 2007).
Unfortunately, it has not had the same success in resource-limited settings, such as
Botswana. The first national strategy for prevention in Botswana, the 2004-2009
National Cervical Cytology Screening Programme, focused on increasing public
awareness of cervical cancer and wide-scale screening with Pap testing (Botswana
MOH, 2011). The initiative was successful in screening thousands of women but left
staggering numbers without treatment. There was insufficient supply of lab equipment
and technicians to handle the influx of cytology slides, which resulted in reporting delays
upwards of one to two years. In addition, treatment options were only hospital-based
with no formal patient recall system, leading to referral bottlenecks for specialist care and
high loss to follow-up for the women that did receive results (Botswana MOH, 2011).
From an epidemiologic perspective, scale-up of an evidence-based, cost-effective
program that attains adequate coverage is needed to achieve reductions in cervical cancer
burden (Edwards & Barker, 2014; Fixsen et al., 2013). Scale-up is defined as “deliberate
efforts to increase the impact of innovations successfully tested in pilot or experimental
projects so as to benefit more people and to foster policy and program development on a
lasting basis” (Edwards & Barker, 2014). Within the field of cervical cancer prevention,
see-and-treat is an innovation that has been shown in clinical trials and pilot testing to be
a safe and effective alternative to Pap smear-based programs (Chung et al., 2013; Consul
et al., 2012; Fokom-Domgue et al., 2015; Nooh et al., 2015; Ramogola-Masire et al.,
2012).
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See-and-Treat. See-and-treat is an alternative prevention method that combines
screening (visual inspection with acetic acid) and treatment (cryotherapy) in a single
visit, greatly reducing opportunities for loss to follow-up. In addition, see-and-treat is
considered more contextually appropriate for resource-limited settings, because it: (1) can
be performed by nurses, (2) uses digital imaging for quality assurance monitoring, and
(3) is cost effective. Visual inspection with acetic acid (VIA) is a simplified procedure
that involves a nurse applying 3-5% dilute acetic acid, or household vinegar, to the cervix
for approximately 3 minutes. Through speculum examination, the nurse visually inspects
the cervix for presence of any lesions, which appear as opaque acetowhite regions to the
naked eye. Identified lesions are treated immediately with cryotherapy, which is a
technique that uses compressed nitrous oxide to freeze and destroy abnormal cervical
cells.
According to the Institute of Reproductive Health, “the ultimate goal in scaling up
a health innovation is to create significant outcomes that address a significant problem at
large scale” (Fixsen et al., 2013). The necessary steps of successful scale-up involve
three phases: pilot, scale-up and large-scale implementation (Fixsen et al., 2013). During
pilot testing, the focus is on accurately measuring the impact of the innovation. The
scaling up phase is marked by emphasis on implementing the innovation with fidelity and
achieving desired coverage. Once the innovation has been successfully scaled-up, the
focus shifts to making sure the innovation is sustainable, continually being implemented
with high fidelity, and creating population-level impact (Barker, Reid, & Schall, 2016;
Edwards & Barker, 2014; A. Fixsen et al., 2013). As described below, see-and-treat in
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Botswana has been proven effective in efficacy and effectiveness research, pilot tested in
the capital city of Gaborone, and scaled-up to 5 additional sites throughout the country.
Efficacy Trials. The efficacy of VIA has been well established in the literature
(Ebisch et al., 2016). Several meta-analyses have been published in recent years that
report pooled sensitivities and specificities for VIA. Regarding sensitivity, VIA has
shown the following ranges: 80% (79%–82%) (Sauvaget, Fayette, Muwonge, Wesley, &
Sankaranarayanan, 2011), 77% (66%–85%) (Mustafa et al., 2016), 77% (75%-78%)
(Chen, Yang, Li, & Li, 2012), and 73.2% (66.5–80.0%) (Qiao et al., 2015). Regarding
specificity, VIA has shown the following ranges: 92% (91%–92%) (Sauvaget et al.,
2011), 82% (67%–91%) (Mustafa et al., 2016), 87% (88%-87%) (Chen et al., 2012),
and 86.7% (82.9%–90.4%) (Qiao et al., 2015). All the meta-analyses mentioned that
there was notable heterogeneity between estimates reported from included studies.
Santesso et. al (2016) conducted a systematic review to determine the harms and benefits
of cryotherapy. They reported a recurrence rate of approximately 5.3% at 12-month
follow-up after treatment. Compared to LEEP and cold knife conization, cryotherapy
had the fewest reported adverse events.
Pilot test. See-and-treat was initially pilot tested from 2009-2011 in the capital
city of Gaborone with 2175 patients (Ramogola-Masire et al., 2012). Nurses were sent
to Zambia for a two-week training on the see-and-treat protocol. Once they returned, the
nurses conducted supervised screenings and treatments until deemed competent by an incountry expert gynecologist. The investigators, Ramogola-Masire et al. (2012),
concluded see-and-treat was “a feasible, high-output and high-efficiency program” . The
protocol used during the pilot test for see-and-treat was originally developed from World
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Health Organization (WHO) guidelines and adapted based on recommendations from an
expert panel of key stakeholders such as clinicians and MOH administrators. Additional
modifications were made to the protocol based on feedback during pilot testing, making it
more contextually appropriate for Botswana. The adapted guideline is referred to
hereafter as the NCCPP see-and-treat algorithm (Figure 1.1).
Scale-up. Botswana’s MOH initiated the 2012-2016 National Cervical Cancer
Prevention Programme in response to the changing landscape of cervical cancer
prevention and new developments for simpler, alternative screening methods to Pap
smear (Botswana MOH, 2011). NCCPP served as a sequel to the 2004-2009 National
Cervical Cytology Screening Programme. NCCPP was a five-year comprehensive
prevention and control strategy that primarily focused on secondary prevention and scaleup of the evidence-based, see-and-treat approach. The strategy was developed through
consultation between the MOH, international and domestic organizations, universities,
NGOs, clinicians, and cancer experts. The target age range was women aged 30-49,
which is the group at highest risk for developing pre-cancerous cervical lesions
(Botswana MOH, 2011; Grover et al., 2015). More than 250,000 women, approximately
25% of all Batswana women, were included in the target age group (Grover et al., 2015).
In 2014, the MOH was confident in the success of the pilot site, running now for 5 years,
and was ready to invest in NCCPP scale-up. The pilot site had been established in the
capitol city of Gaborone. During scale-up, 5 additional sites were developed in Lobatse,
Selebi-Phikwe, Maun, Francistown, and Mahalapye (referred hereafter as scaled-up
sites). At each site, there was a screening clinic and a referral clinic established.
Screening clinics were staffed with nurses who conducted initial VIA and cryotherapy.
9

Referral clinics were located within close proximity, staffed with a medical officer, and
equipped with a colposcopy and LEEP machine. Monthly visits to the scaled-up sites
were conducted by expert physicians and nurses from the pilot site to assist with training,
mentorship, and quality monitoring.
NCCPP remained under the jurisdiction of the MOH. The MOH provided
oversight to the program and ultimately made decisions regarding its direction. The
Botswana-UPenn Partnership (BUP), hired as the implementing partner, was responsible
for coordinating, monitoring, and evaluating the scale-up. During the scale-up, NCCPP
was funded through the Pink Ribbon Red Ribbon Initiative (PRRR). PRRR is a
government program under former President George Bush that recognizes the increased
risk among HIV patients of developing cervical cancer. PRRR aims to improve cervical
cancer screening uptake by utilizing already established infrastructure for HIV
programming. All clinical staff – nurses, medical officers, and physicians – for NCCPP
was employed by the MOH. If avoidable, the MOH agreed that it would try not to move
NCCPP staff to fill greater needs in the country during the scale-up period to prevent
high provider turnover.
Implementation Science
Implementation science offers an innovative perspective to address cervical
cancer burden in resource-limited settings like Botswana. Implementation science aims to
bridge research and practice to ultimately achieve desired patient and population health
outcomes (Brownson et al., 2012). Historically, a significant amount of efficacy and
effectiveness research conducted in controlled settings has not translated into “realworld” impact. Estimates show that it takes an average of 17 years for 14% of original
10

research to affect practice (Brownson et al., 2012). Implementation science seeks to
address this “quality chasm” by explicitly studying the processes of implementing
evidence-based programs in clinical and public health settings and developing strategies
to improve the speed and rigor of research translation (Institute of Medicine, 2001;
Brownson et al., 2012).
Implementation is defined as “an active approach of spreading evidence-based
programs to target audiences via determined channels using planned strategies” (Rabin,
Brownson, Haire-Joshu, Kreuter, & Weaver, 2008). Implementation is a key part of the
equation to creating real world impact that is often overlooked. If the desired health
outcomes are not achieved after an evidence-based program is implemented, the failure is
typically attributed to the program without consideration of how well it was or was not
implemented in that particular setting (Green, Ottoson, Garcia, & Hiatt, 2009a).
Implementation science calls for explicit and rigorous evaluation of the implementation
process to provide useful information about the core elements that need to be in place to
successfully implement an evidence-based program (Greenhalgh, Robert, Macfarlane,
Bate, & Kyriakidou, 2004; Proctor et al., 2011). Implementation research addresses the
need for increased understanding of the contexts in which programs work best and for
what populations, which will help to develop future strategies that can be used to improve
the overall implementation process.
As mentioned previously, the efficacy of see-and-treat has been well established
in SSA (Chung et al., 2013; Consul et al., 2012; Fokom-Domgue et al., 2015; Nooh et
al., 2015; Ramogola-Masire et al., 2012). However, efficacy does not readily and easily
translate into practice. Although see-and-treat has been effective in the pilot test, the
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proven effectiveness demonstrated will not translate into practice if fidelity is not
maintained during the scaled-up of NCCPP.
Fidelity. Fidelity is one of the distinct implementation outcomes defined by
Proctor et al. (2011) and has been explored further in this dissertation. Fidelity is defined
as the “degree to which a practice or intervention is implemented as originally prescribed
in the protocol or as intended by the program developers” (Breitenstein et al., 2010;
Carroll et al., 2007). Fidelity is important to measure, because it provides an indication of
how well and rigorously the implementation process has been conducted. Fidelity is
composed of two key aspects: (1) adherence, the degree to which essential program
elements are implemented and (2) competence, the level of skill maintained throughout
the implementation process (Breitenstein et al., 2010; Carroll et al., 2007).
Adherence. Clinical practice guidelines (CPGs), such as the NCCPP see-and-treat
algorithm, are used to guide providers’ behavior to ensure care delivery is evidence-based
(Amoakoh-Coleman et al., 2016; Ebben et al., 2013). However, CPGs are useless if
providers are not referring to them and employing their recommendations (Fischer,
Lange, Klose, Greiner, & Kraemer, 2016). Guideline adherence in the scale-up of
innovations is imperative to ensuring that intended outcomes are achieved. Risks of not
adhering to guidelines include patients receiving unnecessary diagnostics and/or
inadequate, suboptimal treatments (Fischer et al., 2016). Limited studies in the field of
cervical cancer prevention have measured adherence, especially from the provider
perspective. Typically, studies that have addressed adherence were concerned with
patient adherence, such as compliance to the 3-dose HPV vaccine series. For this
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dissertation, adherence measures how well providers’ treatment and referral choices align
with the NCCPP see-and-treat algorithms.
Competence. VIA is a subjective assessment that requires a trained, keen eye. To
achieve adequate sensitivity and specificity, VIA must be performed with a high level of
competency. Consistent practice and use of VIA helps to maintain competency. Nurses
were initially trained to perform see-and-treat through a 3-day didactic workshop in
Zambia during January 2009 (Ramogola-Masire et al., 2012). Hands-on experience
performing VIA and cryotherapy occurred for two weeks under supervision in Zambia
and six weeks in Botswana. Each nurse was required to perform a minimum of 100 VIA
exams and 35 cryotherapies. Ongoing monitoring of VIA competency is conducted
throughout the program. For each patient visit, nurses are required to take pictures of the
cervix with a digital camera after VIA is performed. This process is referred to as
enhanced digital imaging (EDI) or digital cervicography. Quality assurance meetings
where expert physicians review the pictures and audit the nurses’ VIA assessments are
conducted on a weekly or biweekly basis for programmatic monitoring and evaluation
purposes. For this dissertation, competence measures providers’ skills in performing VIA
screenings.
Barriers. Implementation barriers can impede successful scale-up of health
innovations and compromise implementation fidelity (Yamey, 2012). Countries that
have implemented and scaled-up see-and-treat have cited barriers such as: inadequate
water and electricity supply (Shiferaw et al., 2016), lack of equipment and supplies
(Munthali et al., 2015), equipment malfunction and repair needs (Martin et al., 2014;
Shiferaw et al., 2016), staff retention and heavy workload (Martin et al., 2014; Munthali
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et al., 2015; Shiferaw et al., 2016), competing priorities (Martin et al., 2014), lack of
supervision (Martin et al., 2014; Munthali et al., 2015), and budget restraints (Martin et
al., 2014).
Given the challenges and barriers that providers face in their daily practice, the
overall purpose of this dissertation was to assess providers’ fidelity to NCCPP see-andtreat algorithms and to compare results between pilot and scaled-up sites. While it
was feasible to supervise providers and ensure their fidelity to the program during pilot
testing, evidence suggests that it is increasingly difficult to do so as the program is being
scaled-up. Therefore, I hypothesized that fidelity to the see-and-treat algorithms would
be significantly higher in the pilot site (Gaborone) compared to the scaled-up sites
(Lobatse, Selebi-Phikwe, Maun, Mahalapye, Francistown). Using the pilot site as the
gold standard, I was interested in evaluating how the scaled-up sites
performed. Unfortunately, recordkeeping was not consistent at the scaled-up site and
comparisons could not be made between pilot and scaled-up sites for the competency aim
(Aim 4).
Considering see-and-treat scale-up in Botswana, there are key differences
between sites that might affect scale-up success and compromise implementation
fidelity. To begin, it is important to recognize that the pilot test was implemented under a
controlled research setting and in an urban context where resources are more readily
accessible. The scaled-up sites were implemented in more rural settings and operated in
“real world” circumstances. Scaled-up sites also suffered from decreased resources and
supply chains. In fieldwork, I observed nurses using laboratory grade Lugol’s iodine for
patient care due to missing supplies.
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Secondly, the pilot site functions solely as a screen and treat clinic. Scaled-up
sites incorporate screening and treatment as part of daily clinics, which results in
increased competing priorities and less frequent practice/volume of screenings. The
referral clinic for the pilot site is located at Princess Marina Hospital. The referral clinic
is open five days a week for other clinical operations (meetings, data management, etc.)
but colposcopy and LEEP is officially scheduled one or two times a week. However, a
physician is usually always in-house and can perform the procedure if a patient comes off
schedule. The referral clinics for scaled-up sites are only offered during a specified day
per week. Occasionally, physicians miss clinic days because they are not staffed full time
and have competing demands elsewhere.
Funding also became a challenge toward the end of the scale-up phase. Botswana
reapplied for PRRR funding and anticipated that they would be receiving
it. However, an announcement came out that overall PRRR funding decreased and some
programs would not be funded. The end of the scale-up was marked by uncertainty about
funding, job security, and livelihood of the overall program. The ultimate decision, after
months of anticipation, was that see-and-treat would be defunded. Fortunately, the MOH
and other donors helped to fund the program so that it would continue. When PRRR
ended, the implementing partnership also ended with BUP and was taken
over by Jhpiego. The leadership transition was quite disruptive to the running of
NCCPP.
Innovation
A limited number of articles have explicitly assessed implementation of cervical
cancer prevention programs in SSA. While there were few studies that included
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implementation outcomes, the overwhelming majority measured patient level outcomes,
such as symptomology, cancer rates, cervical lesion typology, etc. For implementation
studies, it is crucial to measure implementation outcomes specifically (Brownson et al.,
2012). Programs that are implemented well will lead to improved patient level outcomes;
however, if we do not measure the implementation outcomes then there is no way to
deduce what is ultimately influencing the patient or population health outcomes.
This dissertation departs from the status quo by focusing on implementation, a
critical but overlooked part of the National Implementation Research Network’s Formula
for Success Model (Duda & Wilson, 2015). The NIRN proposes three key components
that are necessary to achieve socially significant outcomes: effective innovations,
effective implementation, and enabling context. To continue advancing the field of
cervical cancer prevention in SSA, there is a need to expand upon well-established
effectiveness findings and increase focus on studying the implementation and context of
prevention practices and programs. For the purposes of this study, the NIRN Formula to
Success Model was adapted to specify directional relationships between concepts (Figure
1.2). The relationships in this model were not tested in this dissertation but provided
important context for the study. The effective innovation is the NCCPP see-and-treat
algorithm, which has the potential to impact socially significant outcomes such as
reducing cervical cancer prevalence. Effective implementation, however, is a moderator
in the relationship between the innovation and intended outcomes. Lack of effective
implementation can reduce the impact of the innovation on intended outcomes. The
reverse relationship is also true with improved implementation leading to better
outcomes. Fidelity is a key component of effective implementation, which was measured
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in this study. Enabling context is an additional concept that is important to consider and
affects all other components of the model. Through future interviews with key
stakeholders, I will contribute to increased understanding of enabling contexts by
eliciting barriers to and facilitators of NCCPP implementation.
The state of the science for cervical cancer prevention in SSA has been focused
on establishing the efficacy and effectiveness of screening technologies such as VIA.
However, efficacy and effectiveness research does not readily and easily translate into
practice. In Botswana, the see-and-treat approach under the NCCPP algorithm was pilot
tested by Ramongola-Masire et al. (2012), who concluded the program is “feasible and
produces high-output and high-efficiency” (Ramogola-Masire et al., 2012). However,
there were no specific outcomes included in the study that measured the implementation
process. In theory, see-and-treat is more feasible because it is less costly and can be
performed by non-physician providers. Feasibility of the program, however, should not
be assumed solely within the context of a controlled study without consideration of the
factors in “real world” settings that affect implementation. Consequently, the efficacy
established in the pilot study may not translate easily into practice as see-and-treat is
scaled-up to a national level. Therefore, this dissertation has aimed to comprehensively
assess providers’ fidelity in NCCPP and identified issues of adherence and competence.
Chapter 1 has provided important context for understanding the purpose and rationale for
this dissertation. Chapter 2 is a standalone systematic review that identifies
implementation strategies that have been used to improve cervical cancer prevention in
SSA. The remaining chapters focus on analysis of nurses’ fidelity to the NCCPP seeand-treat algorithms. Chapter 3 details the methodology and results are presented in
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Chapter 4. Chapter 5 concludes the body of work with a key discussion of findings and
implications for research, policy, and practice.
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Figures
Figure 1.1 See-and-Treat Algorithm from Botswana’s National Cervical Cancer
Prevention Programme (NCCPP)
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Figure 1.2 Adapted Formula for Success Model

(Fidelity)

Note: The following model has been adapted from the National Implementation
Research Network’s (NIRN) Formula for Success.
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CHAPTER 2: Implementation strategies to improve cervical cancer prevention
in sub-Saharan Africa: A systematic review
Abstract
Background: Developed countries, such as the United States, have achieved significant
decreases in cervical cancer burden since the introduction of Pap smear-based programs
in the 1960s. Due to implementation barriers and limited resources, many countries in
sub-Saharan Africa (SSA) have been unable to attain such reductions. The purpose of
this review was to evaluate implementation strategies used to improve the uptake and
sustainability of cervical cancer prevention programs in SSA.
Methods: Following PRISMA guidelines, a reviewer independently searched PubMed,
Ovid/Medline, Scopus, and Web of Science databases for relevant articles with the
following search limits: English language, peer reviewed, and published between 1996
and 2016. Of the 1979 articles identified in the search, 40 were included in the final
review. Included articles were abstracted for implementation-related content and
evaluated for risk of bias according to study design with the National Heart, Lung, and
Blood Institute’s (NHLBI) Quality Assessment Tools.
Results: The 40 included studies were well represented amongst all sub-Saharan regions:
South (n=14, 35%), East (n=12, 30%), West (n=8, 20%), and Middle (n=6, 15%). Most
studies were conducted in the last 5 years (n=29, 72.5%), with an overall publication date
range from 1996 to 2016. There were 28 cross-sectional studies (70%), 6 randomized
control trials (15%), 5 pre-post tests (12.5%), and one nonrandomized control trial
(2.5%). The majority of studies were “poor” quality (n=18, 45%). Visual inspection
with acetic acid (VIA) (n=16, 40%) was used as the main prevention method more
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frequently than HPV DNA/mRNA testing (n=10, 25%), Pap smear (n=9, 22.5%), and
HPV vaccine (n=7, 17.5%). Effectiveness of strategies to improve program
implementation was measured using implementation outcomes of penetration (n=26,
65%), acceptability (n=13, 32.5%), fidelity (n=10, 25%), feasibility (n=7, 17.5%),
sustainability (n=2, 5%), and cost (n=1, 2.5%). Education strategies (n=29, 72.5%) were
used most often but have shown limited effectiveness.
Conclusion: This systematic review highlights the need to diversify strategies that are
used to improve implementation for cervical cancer prevention programs. While
education is important, implementation science literature reveals that education is not as
effective in generating change. There is a need for additional organizational support to
further incentivize and sustain improvements in implementation.
Keywords: Cervical cancer, Prevention, Program implementation, Implementation
strategies, Sub-Saharan Africa
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Background
Cervical cancer is a high-burden global health issue, with an estimated 528,000
new cases and 266,000 deaths in 2012 for women across the world (GLOBOCAN,
2012). Most of the global burden (85%) lies in less developed countries, with regions in
sub-Saharan Africa (SSA) having the largest age-standardized incidence and mortality
rates (GLOBOCAN, 2012). Developed countries, such as the United States, have
achieved significant decreases in cervical cancer burden since the introduction of
organized Pap smear programs in the 1960s (Jemal et al., 2012; Safaeian et al., 2007).
However, many countries in SSA have been unable to attain such reductions due to
implementation barriers and resource limitations (Chidyaonga-Maseko et al., 2015;
Denny et al., 2006; Lim & Ojo, 2017; McFarland et al., 2016; Randall & Ghebre, 2016).
In fact, cervical cancer rates are expected to continue rising despite efforts to implement
national screening and treatment programs (De Vuyst et al., 2013). Cervical cancer
remains the most commonly diagnosed cancer and leading cause of cancer-related death
in African women south of the Sahara (GLOBOCAN, 2012).
Untangling the causes for high cervical cancer burden in SSA is difficult due to a
complex interplay of many biological, organizational, economic, and sociocultural
factors. For example, HIV has been correlated with an increased risk for developing
cervical cancer (Mapanga, Elhakeem, Feresu, Maseko, & Chipato, 2017). HIV infection
causes the body to become immunocompromised and more susceptible to contracting
HPV, which is a significant precursor to cervical cancer (Mapanga et al., 2017). SSA
incidentally carries a high HIV/AIDS burden, accounting for 71% of the global
population living with HIV (Kharsany & Karim, 2016). Furthermore, young women
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bear a disproportionate burden compared to their male peers [11]. Other contributory
factors include the aging and growth of the population, limited access to medical
facilities, poor nutrition, severity of disease at presentation, and insufficient facilities for
treatment (Anorlu, 2008; Denny & Anorlu, 2012; Louie, de Sanjose, & Mayaud, 2009;
Ntekim, 2012). While these factors contribute to the rise in cervical cancer for this
region, this paper focused on the need for improved implementation of existing
prevention programs and the promise that increased access to preventive services has on
decreasing burden.
Prevention is key. With adequate resources, precancerous cervical lesions are
easily prevented and treatable (Denny & Wright, 2009; Fiander, 2011). The incubation
period between HPV infections potentially developing into cervical cancer is 10 to 20
years, which allows ample opportunities to screen, track, and treat across the disease
progression ("Cancers of the female reproductive organs", 2014). In addition, numerous
technologies have been developed to detect and treat precancerous lesions including: Pap
smear, colposcopy, visual inspection with acetic acid or Lugol’s iodine (VIA/VILI), HPV
DNA testing, cone biopsy, cryotherapy (cryo), and loop electrosurgical incision
procedure (LEEP) (Mishra et al., 2011; Safaeian et al., 2007). Although these tools have
been proven safe and effective (Adefuye, Broutet, de Sanjose, & Denny, 2013), there are
still significant challenges in implementing them into comprehensive national screening
and treatment programs.
For decades, developed countries have used cytology-based programs with Pap
smear as the standard screening protocol (Denny et al., 2006; Jemal et al., 2012; Safaeian
et al., 2007). However, these programs require lab infrastructure that is not readily
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available in many SSA countries and is often prohibitively expensive to sustain on a large
scale (Sankaranarayanan et al., 2013).

Alternative screening methods have been

developed with the hope of being more sustainable in resource-limited settings (Denny et
al., 2006). Visual inspection with acetic acid and Lugol’s iodine (VIA/VILI) are visual
tests that are used to identify precancerous lesions with the naked eye. VIA and VILI are
advantageous because they can be performed by non-physician providers (addressing
provider shortages) and provide immediate results (reducing loss to follow-up) (Asgary et
al., 2016; Horo et al., 2012; Ramogola-Masire et al., 2012). VIA and VILI have similar
sensitivity when compared to Pap smear and can provide screening at a much lower cost
and with fewer staff needed (Adefuye et al., 2013; Quinley et al., 2011a; RamogolaMasire et al., 2012). However, these visual tests are less specific than Pap testing and can
lead to overtreatment (Adefuye et al., 2013; Ramogola-Masire et al., 2012). HPV DNA
testing is another alternative screening method that is used to identify high risk,
carcinogenic HPV (typically types 16 and 18). The test can be performed at home with
self-sampling kits and has been deemed acceptable by women (Lack et al., 2005;
Safaeian et al., 2007; Sossauer et al., 2014; Ting et al., 2013; Untiet et al., 2014; van de
Wijgert et al., 2006). It can also be used as a preliminary triage to save time and
resources on women that screen HPV negative and do not require follow-up testing
(Catarino, Petignat, Dongui, & Vassilakos, 2015; Lorincz, Castanon, Lim, & Sasieni,
2013). HPV DNA testing does not require the same level of lab infrastructure as Pap
smear, but it involves lab processing nonetheless and wait times to receive results
(Denny et al., 2006).
Despite development of alternatives to Pap smear, a significant research-to25

practice gap still exists.

Lack of trained providers, overburdened health facilities,

insufficient supplies, inadequate lab infrastructure, loss to treatment follow-up, high
costs, and cultural beliefs are some of the implementation barriers experienced in SSA
(Chidyaonga-Maseko et al., 2015; Denny et al., 2006; Lim & Ojo, 2017; McFarland et
al., 2016; Randall & Ghebre, 2016).

In addition to seeking alternative screening

methods, SSA countries can further improve their prevention efforts by developing and
employing implementation strategies to overcome these barriers. An implementation
strategy is defined as “a systematic intervention process to adopt and integrate evidencebased health innovations into usual care” (Powell et al., 2012). The purpose of this
systematic review was to uncover the breadth and diversity of implementation strategies
used to improve the uptake and sustainability of cervical cancer prevention programs in
SSA. Through highlighting different strategies, we aimed to assist researchers,
practitioners, managers, and policy makers in scaling up and evaluating new and existing
programs.
Methods
Search Strategy
Figure 2.1 outlines the search strategy, which was developed using Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines
(Liberati et al., 2009; Moher, Liberati, Tetzlaff, Altman, & PRISMA Group, 2009). A
reviewer independently searched PubMed, Ovid/Medline, Scopus, and Web of Science
databases with the following search terms: (sub-Saharan Africa) AND (cervical cancer)
AND (prevention OR program implementation OR HPV vaccine OR Pap smear OR seeand-treat OR VIA OR VILI OR colposcopy OR LEEP OR cryotherapy).
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Eligibility Criteria
Inclusion and exclusion criteria were developed and applied during full text
review to identify original research that empirically evaluated or tested discrete
implementation strategies to improve cervical cancer prevention in SSA. Articles were
eligible for inclusion if written in English, peer reviewed, and published between 1996
and 2016. Non-empirical studies (reviews, commentaries, editorials, etc.) and studies
that did not explicitly assess implementation strategies (knowledge, attitudes, and beliefs;
incidence and prevalence; safety and efficacy; cost effectiveness and modeling) were
excluded from the review.
Study Selection
The initial search yielded 1979 articles. Titles and abstracts of the identified
articles were screened to exclude duplicates (n=966) and studies not relevant to the topic
(n=252). The remaining articles (n=761) were reviewed in full text. 40 studies met the
eligibility criteria and an additional 721 articles were excluded.
Data Extraction
The 40 articles that fit the inclusion criteria were extracted for the following
implementation-related content: title, author, publication year, purpose, country, study
design, prevention tools, implementation strategies, implementation outcomes, and
results. Two seminal articles from implementation science, Proctor et al 2011 (Proctor et
al., 2011) and Powell et al 2012 (Powell et al., 2012), were used to define and categorize
implementation outcomes and strategies, respectively. A complete list of categories and
their definitions for implementation outcomes and strategies can be found in Table 2.1.
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Quality Screening
Quality assessment tools from the National Heart, Lung, and Blood Institute
(NHLBI) were used to assess each study for internal validity (NHLBI, 2014). There are
separate NHLBI Quality Assessment Tools for each study type (controlled trials, preposttest, and cross-sectional). Each tool includes specific questions to assess bias,
confounding, power, and strength of association between intervention and outcomes. The
answer to each question can be “yes”, “no”, “cannot determine”, “not reported”, or “not
applicable”. Instead of using a numeric scoring system, the rater is asked to consider
potential risk for bias in the study design whenever a “no” is selected. Overall quality
ratings are scored as “good” (low risk of bias, valid results), “fair” (some risk of bias,
does not invalidate results), or “poor” (significant risk for bias, may invalidate results).
One reviewer independently screened all studies, and a second reviewer screened a 20%
sample (n=8) to double-check for accuracy.
Results
Of the initial 1979 articles, 40 met inclusion criteria and were included in the
following synthesis of results. Study characteristics are summarized in Table 2.2. The
table of evidence is included as Table 2.3. All studies were written in English and peerreviewed. While most studies were published within the last 5 years, publication dates
range from 1996 to 2016. Studies were well represented in all regions of sub-Saharan
Africa with 14 of the total studies (35%) conducted in Southern Africa, 12 (30%) in
Eastern, 8 (20%) in Western, and 6 (15%) in Middle.
Study Design
Most studies included in the review were cross-sectional (n=28, 70%). Eight of
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the cross-sectional studies similarly evaluated the impact of changing service providers
on how well the screening test is performed. Using specificity and sensitivity rates, some
studies compared VIA assessments between nurses and an expert physician (Asgary et
al., 2016b; Firnhaber et al., 2015a; Quinley et al., 2011a; Ramogola-Masire et al., 2012)
while others compared self- vs. physician- collected samples for HPV DNA testing
(Lack et al., 2005; Safaeian et al., 2007; Ting et al., 2013; Untiet et al., 2014). Twelve
studies examined if screening coverage increases when changing service sites (Ladner et
al., 2012; LaMontagne et al., 2011; Megevand, Van Wyk, Knight, & Bloch, 1996;
Ogembo et al., 2014), combining screening with an already established program (i.e.
HIV/STI screening) (Huchko, Bukusi, & Cohen, 2011; Khozaim et al., 2014; Maree, Lu,
& Wright, 2012; Moodley, Tathiah, Mubaiwa, & Denny, 2013; Moon et al., 2013;
Snyman, Dreyer, Visser, Botha, & van der Merwe, 2015; Were, Nyaberi, & Buziba,
2010), or providing financial incentives (Mehrotra, An, Patel, & Sturm, 2014). Five
studies evaluated the effect of educational interventions on knowledge, attitudes, and
screening behaviors for patients (Kapambwe et al., 2013) and providers (Crofts et al.,
2015; Dim, Onyedum, Dim, & Chukwuka, 2015; Wamai et al., 2012). Three studies
examined if reminder systems can help to decrease lost to follow-up rates through
community health workers (Goldhaber-Fiebert, Denny, De Souza, Kuhn, & Goldie,
2009; Tum, Maree, & Clarke, 2013) or phone-based tracking (Horo et al., 2012).
Five studies (12.5%) were conducted with a pre-posttest design. All of the prepost studies evaluated the effectiveness of educational interventions in improving
awareness and screening behaviors for patients (Abiodun, Olu-Abiodun, Sotunsa, &
Oluwole, 2014; Dreyer et al., 2015; K. O. Wright, Kuyinu, & Faduyile, 2010) or
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knowledge and skills retention for providers (Levine, Chudnoff, Taylor, Baganizi, &
Banks, 2011; Miller et al., 2007). Only two studies included a control group (Abiodun et
al., 2014; K. O. Wright et al., 2010).
There were 6 randomized control trials (15%). Five trials tested strategies to
increase screening uptake through educational interventions (Risi et al., 2004; Rosser,
Njoroge, & Huchko, 2015; Sossauer et al., 2014), financial incentivizes (Okeke, Adepiti,
& Ajenifuja, 2013), or changing service sites (Watson-Jones et al., 2012). One trial
compared HPV DNA self-sampling to the current standard of physician collection via
speculum exam (van de Wijgert et al., 2006).
Only one study was a non-randomized control trial (2.5%). Mutyaba et al.
(2009) evaluated if male partner involvement was effective in reducing loss to follow-up
after a positive VIA screening test.
Prevention Tools
Primary prevention with HPV vaccine was included in 7 studies (17.5%). VIA
was the most frequently used secondary screening method (n=16, 40%). Less commonly,
secondary screening was completed with HPV DNA/mRNA testing (n=10, 25%), Pap
smear (n=9, 22.5%), colposcopy (n=7, 17.5%), biopsy (n=4, 10%), and unspecified
screening (n=4, 10%). Digital imaging to supplement visual screening methods
(VIA/VILI) was used in seven studies (17.5%). If follow-up treatment of precancerous
lesions was conducted, it was either performed with loop excisional procedure (LEEP)
(n=4, 10%) or cryotherapy (n=4, 10%).
Implementation Strategies
Researchers used educate (n=29, 72.5%), restructure (n=20, 50%), and quality
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(n=11, 27.5%) strategies most frequently in their studies. For patients and their families,
education strategies aimed to increase cervical cancer awareness and the importance of
prevention. For providers, education strategies were used to improve knowledge and
skills retention in conducting screening and treatment services such as VIA, cryotherapy,
and LEEP. Example educate strategies included community outreach, individual patient
teaching and counseling, provider training, mass media campaigns, and development of
educational materials. Restructure strategies were used to facilitate implementation by
changing service sites (established vs. mobile clinic for Pap smear), changing delivery
models (age- vs. class-based for HPV vaccine), or changing providers (nurse vs.
physician for VIA, patient vs. physician for HPV DNA test). Several studies also used
the restructure strategy to combine cervical cancer prevention with other services (i.e.
HIV/STI testing, marriage counseling, family planning) to improve the financial and
infrastructural support provided through already established programs. The quality
strategies included in these studies were ongoing consultation, patient reminder systems,
and audit-feedback mechanisms. Two studies (5%) included a finance strategy to
incentivize patients to uptake screening services. Only one study (2.5%) utilized the plan
strategy. Kapambwe et al. (2013) spent time developing trust with alangizi (traditional
marriage counselors) to encourage them to integrate cervical cancer screening messaging
into their counseling sessions with women. There were no policy strategies (0%) in the
included studies.
Implementation Outcomes
The most studied implementation outcomes were penetration (n=26, 65%),
acceptability (n=13, 32.5%), fidelity (n=10, 25%), and feasibility (n=7, 17.5%).
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Penetration was often measured as vaccine or screening coverage, which is calculated by
dividing the number of women who participated by the total eligible or targeted
population. Additional measures of penetration included rates of loss to follow-up for
cryotherapy or LEEP treatment and 3-dose adherence for HPV vaccination.
Acceptability was most commonly measured by surveying patients to determine reasons
why they accepted or refused participation. Amongst providers, acceptability was
measured as comfort with performing newly learned skills and reported satisfaction with
training and program implementation. To measure feasibility, many researchers
determined providers’ perceived barriers and facilitators to implementation. Other
studies quantified circumstances that impeded successful operation of the program such
as rates of equipment malfunction, poor picture quality for digital images, invalid lab
results, and expired vaccines.
Other less frequently studied outcomes included fidelity (n=10, 25%) and
sustainability (n=2, 17.5%). Fidelity was measured in studies that compared either
nurses’ VIA assessments or self-collected HPV DNA samples to that of expert
physicians. These comparisons indicated whether patients and nurses can perform these
tests with reasonable reliability and help to address physician shortages by alternatively
implementing the screenings. Only two studies included measures of sustainability.
Moon et al. (2013) quantified sustainability by the number of providers that were still
performing VIA one year after initial training. Levine et al. (2011) determined VIA skill
and knowledge retention with a 6-month follow-up assessment.
There were no studies that measured adoption (0%) or appropriateness (0).
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Quality Assessment
Few studies (n=8, 20%) were determined to be of “good” quality using the
NHLBI Quality Assessment Tools. The remaining studies were “fair” (n=14, 35%) or
“poor” (n=18, 45%). Overall, many studies did not sufficiently describe their
methodology, which made it difficult to make determinations for items on the NHLBI
tools. Items were often marked as “not specified” or “cannot be determined”. A
common weakness specifically for controlled intervention studies was a lack of adequate
randomization. Some randomized control trials (RCTs) used a preset plan for allocating
patients to intervention or control groups (i.e. even vs. odd ID numbers) instead of using
computer-generated lists. Other RCTs did not provide any description for how
participants were allocated. Adequate randomization is important as it provides
confidence that results are attributable to the intervention rather than a difference in
groups at baseline. For pre-posttests, only 2 of the 5 studies included a control group
(Abiodun et al., 2014; Wright et al., 2010). Without a control group for comparison, there
is less confidence that an improvement between pre- and post- assessments is due to the
intervention rather than mere chance. The cross-sectional studies were mainly
descriptive. Limited cross-sectional studies used statistical analyses to determine
associations between intervention and outcomes. Confounders were rarely measured and
included in the analyses. Outcome measures frequently lacked validity and reliability.
Discussion
Through conducting this literature search, the authors found no review to date that
addresses the implementation of cervical cancer prevention programs in SSA. However,
Finocchario-Kessler et al (2016) conducted a systematic review of the literature between
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2004 and 2014 to characterize the cervical cancer research in SSA according to four
public health categories (primary prevention, secondary prevention, tertiary prevention,
and quality of life). The authors determined that most studies focused on secondary
prevention and concluded that there is a need for “implementation science research to
inform feasible and sustainable strategies to maximize the number of women reached
with services” (Finocchario-Kessler et al., 2016). There is a significant research-topractice gap. Safe and effective prevention tools exist but are not reaching the women
that need these services most. This review is an attempt to enter cervical cancer
prevention into the implementation science conversation to propel the state of the science
forward.
Implementation science is an emerging field that aims to bridge research and
practice to ultimately achieve desired patient and population health outcomes (Brownson
et al., 2012). Historically, a significant amount of efficacy and effectiveness research
conducted in controlled settings has not translated into “real-world” impact. The
traditional, passive methods of dissemination (i.e. journal publishing) have not proven
effective. Estimates show that it takes an average of 17 years for 14% of original research
to effect practice (Green, Ottoson, Garcia, & Hiatt, 2009). Implementation science seeks
to address this “quality chasm” by explicitly studying the processes of implementing
evidence-based programs in clinical and public health settings (Institute of Medicine,
2001). Implementation strategies are instrumental in bridging the gap and improving the
speed and rigor of research translation. The results from this review provide insight into
how study design, strategies, and outcomes have been used to study implementation of
cervical cancer prevention in SSA. Since sub-Saharan Africa faces some of the highest
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cervical cancer rates worldwide, it is important to evaluate what has been done so far to
address these challenges and contemplate how these efforts can be improved through use
of implementation strategies.
Study Design
While randomized control trials are the “gold standard” in efficacy and
effectiveness research, these study designs are difficult to feasibly conduct in
implementation research due to the use of multi-level, multi-strategy interventions
(Brownson et al., 2012). It is more difficult to conduct random assignment when the level
of analysis is at the organization-, community-, and/or country-level rather than the
individual-level. It is also difficult to produce large enough sample sizes to create
adequate statistical power. For these reasons, Brownson, Colditz & Proctor (2012)
concludes in Dissemination and Implementation Research in Health, one of the seminal
works to progress the field of implementation science, that quasi-experimental designs
without randomization are reasonable for implementation research. However, they argue
that rigorous quasi-experimental design is essential to achieving quality data that has
practical use. While quasi-experimental studies may be more feasible to conduct, these
designs do not produce the same level of confidence in causation as randomized control
trials and make it more difficult to compare effectiveness between different studies.
In the absence of randomization, researchers can incorporate control groups,
confounders, and statistical comparison of baseline group characteristics to greatly
increase rigor of implementation study designs. In their assessment of 66 Cochrane
reviews on implementation research, Brownson Colditz & Proctor (2012) concluded that
“many publications in the literature are still merely descriptive in nature or have weak
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designs without comparison or control conditions to answer critical research questions”.
This systematic review produced similar results. Most studies were cross-sectional,
descriptive studies and assessed as “poor” quality. This review echoes the argument that
there is a need for more rigorous research designs that meet the needs of implementation
science questions.
Implementation Strategies
Evaluating effectiveness for the various implementation strategies is difficult due
to the descriptive nature of most studies, overall poor quality in study designs, and
variation in outcomes measured. While educate strategies were the most popular method
leveraged in attempt to improve implementation, implementation science suggests that
dissemination of information is not the most effective method for creating sustainable
change ( Fixsen, Naaom, Blase, Friedman, & Wallace, 2005). Within this literature
review, education also failed to produce intended outcomes. Many studies that employed
educate strategies showed improvements in awareness. However, these strategies in
isolation have not always catalyzed better uptake, acceptability, and/or confidence
(Crofts et al., 2015; Rosser et al., 2015; Tum et al., 2013; Wamai et al., 2012). If a
significant difference was observed, uptake still remained low (Abiodun et al., 2014;
Mutyaba et al., 2009; Risi et al., 2004). These results suggest a need to diversify
implementation strategies used to improve cervical cancer prevention in this context.
Restructure, finance, and attend to policy context strategies can provide the
organizational support required to improve implementation and overcome barriers of
resource-limited settings.
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Implementation Outcomes
While there were implementation outcomes included in these studies, the
overwhelming majority were patient-level outcomes, such as symptomatology, cancer
rates, cervical lesion typology, etc. For implementation studies, it is crucial to measure
implementation outcomes specifically (Proctor et al., 2011). If the desired health
outcomes are not achieved after an evidence-based program is implemented, the failure is
typically attributed to the evidence-based program without consideration of how well the
practice was or was not implemented in that particular setting (Fixsen et al., 2005; Green
et al., 2009b). If we do not measure implementation outcomes, there is no way to deduce
what is ultimately influencing the patient or population health outcomes. Additionally,
there is a need for continued effort in operationalizing and measuring implementation
outcomes. Two of the 7 outcomes (adoption and appropriateness) were not measured in
the review and should be considered for inclusion in future studies.
Limitations
A major limitation of this systematic review is the overall quality of studies.
“Poor” quality ratings for most studies made it difficult to make conclusions about
implementation strategies and their effectiveness. Risk of bias in study design and
implementation greatly decreased confidence in the validity of results. Another
limitation is that one reviewer independently screened articles for inclusion and
completed quality assessments. To ensure accuracy, a sample of initial articles was
screened and quality assessed by a second reviewer. Inconsistencies were resolved
through consensus before the primary reviewer proceeded with the remaining articles.
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Conclusions
This systematic review suggests the need to diversify strategies that are used to
improve implementation for cervical cancer prevention programs. While education is
important, implementation science literature reveals that dissemination of information in
isolation is not as effective in generating change (Fixsen et al., 2005). There is a need
for additional organizational support to further incentivize and sustain change
(Brownson et al., 2012; Helfrich, Weiner, McKinney, & Minasian, 2007).
Implementation research is difficult, because interventions are multifaceted and
conducted at different levels of analysis (Brownson et al., 2012). Many studies in this
review included patient level outcomes but did not include implementation specific
outcomes to assess the success of implementation strategies. This review calls for an
increased use of implementation science frameworks to inform the design of studies that
aim to improve cervical cancer prevention in SSA. This review also calls for increased
use of common terminology from implementation science for outcomes and strategies.
Implementation science can help to communicate results between researchers and
increase rigor of research design to better isolate impact of implementation strategies on
intended outcomes.
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Figures and Tables

Identification

Figure 2.1 Search Strategy
Records identified through
database searching
(n = 1979)
Scopus (158)
Web of Science (167)
Ovid/Medline (780)
Pubmed (874)

Included

Eligibility

Screening

Records after duplicates removed
(n = 1013)

Records screened
(n = 1013)

Full-text articles
assessed for eligibility
(n = 761)

Studies included in
qualitative synthesis
(n = 40)

Records excluded
(n = 252)
Not Topic, Language

Full-text articles excluded,
with reasons
(n = 721)
Non empirical studies
(review/commentary) or
studies that did not
include implementation
strategies
(knowledge/attitude/belie
fs, incidence/predictors,
safety/efficacy/effectiven
ess, costeffectiveness/modelling)

Note: The search strategy was developed based on PRISMA guidelines.
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Table 2.1 Categories and Definitions for Implementation Outcomes and Strategies

Implementation Outcome

Definition*

Acceptability

Perception among implementation stakeholders
that a given treatment, service, practice, or
innovation is agreeable, palatable, or satisfactory.

Adoption

Intention, initial decision, or action to try or
employ an innovation or evidence-based practice

Appropriateness

Perceived fit, relevance, or compatibility of the
innovation or evidence based practice setting,
provider, or consumer; and/or perceived fit of
innovation to address a particular issue

Penetration

Integration of a practice within a service setting
and its subsystems. Number of eligible persons
who use a service, divided by the total number of
persons eligible for the service. Number of
providers who deliver a given service or treatment,
divided by the total number of providers trained in
or expected to deliver the service

Feasibility

Extent to which a new treatment, or an innovation,
can be successfully used or carried out within a
given agency or setting

Fidelity

Degree to which an intervention was implemented
as it was prescribed in the original protocol or as it
was intended by the program developers

Sustainability

Extent to which a newly implemented treatment is
maintained or institutionalized within a service
setting’s ongoing, stable operations.

Implementation Cost

Cost impact of an implementation effort

Implementation Strategy
Plan
•
•
•
•

Gather information
Build buy-in
Initiate leadership
Develop relationships

Definition*
Help stakeholders gather data, select strategies,
build buy-in, initiate leadership, and develop the
relationships necessary for successful
implementation
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Educate
• Develop materials
• Inform and influence
stakeholders

Inform a range of stakeholders about the
innovation and/or implementation effort

Finance
• Modify incentives
• Facilitate financial
support

Incentivize the use of clinical innovations and
provide resources for training and ongoing support.

Restructure

Facilitate implementation by altering staffing,
professional roles, physical structures, equipment,
and data systems

Quality Management

Put data systems and support networks in place to
continually evaluate and enhance quality of care,
and ensure that clinical innovations are delivered
with fidelity

Attend to Policy Context

Encourage the promotion of clinical innovations
through accrediting bodies, licensing boards, and
legal system

Note: Definitions for implementation outcomes and strategies have been cited in Proctor
et al. (2011) and Powell et al. (2012), respectively.
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Table 2.2 Summary of Study Characteristics (N=40)

Sub-Saharan Region
South
East
West
Middle
Country
South Africa
Cameroon
Kenya
Nigeria
Uganda
Botswana
Tanzania
Ghana
Cote d’Ivoire
Zambia
Gambia
Mozambique
Publication Date
1996-2000
2001-2005
2006-2010
2011-2016
Study Design
Cross-sectional
Randomized Control Trial
Pre-post Test
Nonrandomized Control Trial
Prevention Tool
VIA
HPV DNA or RNA Test
Pap Smear
HPV vaccine
Colposcopy
Digital Imaging
VILI
Cryotherapy
LEEP
Biopsy
Unspecified Screening

Number of
studies (N)

Percentage
of total
studies (%)

14
12
8
6

35
30
20
15

12
6
5
5
4
2
1
1
1
1
1
1

30
15
12.5
12.5
10
5
2.5
2.5
2.5
2.5
2.5
2.5

1
2
8
29

2.5
5
20
72.5

28
6
5
1

70
15
12.5
2.5

16
10
9
7
7
7
6
4
4
4
4

40
25
22.5
17.5
17.5
17.5
15
10
10
10
10
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Implementation Strategy
Educate
Restructure
Quality
Finance
Plan
Attend to Policy Context
Implementation Outcome
Penetration
Acceptability
Fidelity
Feasibility
Sustainability
Cost
Adoption
Quality Assessment
Poor
Fair
Good

29
20
11
2
1
0

72.5
50
27.5
5
2.5
0

26
13
10
7
2
1
0

65
32.5
25
17.5
5
2.5
0

18
14
8

45
35
20
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Table 2.3 Table of Evidence (N=40)
First
Author,
Year

Purpose

Country

Program

Strategy

Outcome

Results

Quality

Randomized Control Trials

(Okeke
et al.,
2013)

Determine the
effect of cost
on screening
uptake by
providing
randomly
priced
subsidies to
eligible women

(Risi et
al., 2004)

Evaluate the
effectiveness of
two media
interventions—
a photo-comic
and a radiodrama—in
increasing
cervical
screening
uptake

(Rosser
et al.,
2015)

Evaluate a
health talk’s
impact on
cervical cancer
knowledge,
attitudes, and
screening rates
in a rural
setting

(Sossauer
et al.,
2014)

Evaluate
whether an
educational
intervention
would improve
women’s
knowledge and
confidence in
the Self-HPV

Nigeria

South
Africa

Kenya

Cameroon

VIA

Finance:
lottery for
varied prices
of screening
and
treatment
subsidies (0,
50, and 100
Naira)

Penetration:
VIA
screening
coverage

Educate:
educational
photo-comic
and radiodrama

Penetration:
Pap smear
screening
coverage

Unspecifi
ed
screening

Educate:
30-minute
didactic
lecture

Acceptabilit
y:
willingness
to screen and
reasons for
refusal
Penetration:
screening
coverage

HPV
DNA test

Educate:
individual
counseling
(all),
educational
video
(intervention
group

Pap smear

Acceptabilit
y:
confidence,
embarrassme
nt, pain,
anxiety,
discomfort,
degree of

Price of screening
had a significant
effect on the
demand for
screening: reducing
the price by 10
cents increased
uptake by 1%.
7% (18 of 269) of
women who
received the
intervention photocomic reported
cervical screening
during the 6 months
follow-up,
compared with 6%
(25 of 389) of
controls (p= 0.89).
Women who
recalled hearing the
radio-drama were
more likely to
report attending
screening (9 of 53,
17%) than those
who did not (19 of
429, 4%; p< 0.001).
Mean knowledge
scores increased by
26.4% in the
intervention arm
compared to only
17.6% in the
control arm (p <
0.01). Screening
uptake was
moderate in both
the intervention and
control arms, with
no difference
between the groups
(58.9% vs. 60.9%,
p = 0.60).
Participants who
received the
educational
intervention had
significantly higher
knowledge about
HPV and cervical
cancer than the
control group but

Fair

Good

Fair

Fair
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method

(van de
Wijgert
et al.,
2006)

(WatsonJones et
al., 2012)

Assess the
validity,
feasibility, and
acceptability of
2 methods of
self-sampling
(tampon or
vaginal swab)
compared to
clinician
sampling
during a
speculum
examination

Compare
coverage
achieved by 2
different
delivery
strategies
(class-based vs.
age-based) for
HPV vaccine
amongst
schoolgirls

relaxation
and
confidence.

South
Africa

Tanzania

HPV
DNA test

Restructure
: selfadministrati
on with
tampon or
vaginal
swab vs.
clinician
collected
swabs

HPV
vaccine

Educate:
community
outreach
with
lectures,
pamphlets,
posters,
radio
messages,
and dramas
Restructure
: change
delivery
models
class-based
vs. agebased

Acceptabilit
y: perceived
pain,
satisfaction
Feasibility:
proportion of
invalid labs
Fidelity:
sensitivity
and
specificity
between
clinician-and
selfcollected
samples

Acceptabilit
y: Reasons
for refusal
Penetration:
HPV vaccine
coverage and
3 dose
adherence

no significant
difference on SelfHPV acceptability
and confidence in
the method.

Sensitivity for highrisk HPV was good
for vaginal swabs
(79.8%) and
moderate for
tampons (59.5%).
Self- and cliniciansampling were rated
as good or okay by
the majority of
women

Poor

For each dose,
coverage was
higher in classbased schools than
in age-based
schools (dose 1:
86.4% vs 82.0% [p
= .30]; dose
2:83.8% vs 77.8%
[p = .05]; and dose
3: 78.7% vs 72.1%
[p = .04]).

Poor

Nonrandomized Control Trial

(Mutyaba
et al.,
2009)

Evaluate the
efficacy of
male partner
involvement in
reducing loss to
follow-up
among women
in Uganda
referred for
colposcopy
after a positive
cervical cancer
screening test

Uganda

VIA,VILI
,
Colposco
py

Educate:
group
lecture,
incentivize
follow-up
with
inclusion of
male partner
by sending
educational
pamphlet
home for
partners

Penetration:
screening
coverage, loss to
follow-up

Intervention
group was
significantly
more likely to
return for
colposcopy than
the control
group, with
16% and 34%,
respectively,
lost to followup.

Poor

Penetration:
screening
coverage

There was a
statistically
significant
difference in
cervical cancer

Good

Pre-Post Tests

(Abiodun
et al.,
2014)

Determine the
effect of health
education on
the awareness,
knowledge and

Nigeria

Unspecifi
ed
screening

Educate:
one-day
health
education
intervention
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(Dreyer
et al.,
2015)

perception of
cervical cancer
and screening
among women
in rural
communities

with group
didactic
lectures and
an
educational
movie

Measure
changes in
knowledge and
screening
behavior after
an educational
intervention
provided to
mothers of
adolescent
HPV vaccine
recipients

Educate:
15-minute
didactic
lecture and
educational
pamphlets
Restructure
: integrate
screening of
mothers into
child HPV
vaccination
program

South
Africa

Pap
smear,
HPV
DNA test

(Levine
et al.,
2011)

Determine the
effectiveness of
an educational
program in
VIA
knowledge and
skills retention
among
healthcare
providers in 2
countries

Uganda

VIA

Educate: 5day
educational
program for
providers
with didactic
lectures and
procedural
training in
VIA

(Miller
et al.,
2007)

Evaluate a train
the trainer
program for
cervical

Nigeria

VIA,
VILI, Pap
smear,
Cryothera

Educate: tr
ain the
trainer in
implementat

Penetration:
screening
coverage

Acceptability:
provider
reported comfort
with skills
Sustainability:
skill assessment
at 6-month
follow-up

None

awareness,
perception,
knowledge and
screening
uptake between
intervention and
control groups.
Proportion of
women in the
intervention
group who had
undertaken
screening rose
from 4.3% to
8.3% (p= .038).
Knowledge
about symptoms
(p< .005),
screening (p<
.005), and
vaccination (p<
.05) improved
significantly at
6-month
retesting.
Improvement
for reported
screening in the
past 12 months
was more
favorable in
Gauteng (41%)
with self-sample
than in Western
Cape with Pap
smear (26%).
Mean test
scores increased
significantly
after
participation in
the training
session (62%
vs. 81%,
p<.001). Selfreported
comfort level
for identifying
cellular
abnormalities
also increased
(2.1 vs. 3.3;
p<0.001 There
was no
significant
difference
between initial
and 6-month
follow-up test
scores (80% vs.
79%).
Of the 41
evaluable
exams, 9 saw no
change, 31

Fair

Poor

Poor
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screening
implementation
and assess prepost knowledge
of the
implementation
process

(Wright
et al.,
2010)

Evaluate the
effect of a
health
education
program on
knowledge of
cervical cancer
amongst
market women
in an urban
area

py

Nigeria

ion

Pap smear

Educate:
develop
pamphlets,
community
outreach

showed
improvement, 1
scored worse.

None

Significant
increase in
proportions
were found in
the
intervention/exp
erimental group
on awareness of
cervical cancer
(61.7%),
associated
symptoms and
risk factors such
as early sexual
debut,
promiscuity and
smoking.

Fair

Agreement rate
between all VIA
diagnoses made
by all CHNs
and the expert
reviewer was
95%. Cohen κ
statistic was
0.67 (95% CI =
0.45–0.88).
Images for 9
patients, taken
by 6 CHNs,
were unclear.

Fair

Overall,
participants
showed high
acceptability
scores for HPV
self-testing
(6.986 of 24),
with lower
scores being
more favorable.
However, there
was no
difference in
acceptability
between
participants
with good vs.
poor knowledge

Fair

Cross-sectional Studies

(Asgary
et al.,
2016b)

(Crofts
et al.,
2015)

Evaluate the
feasibility and
efficacy of
ongoing,
smartphonebased support
in sustaining
VIA skills for
community
health nurses

Report on
women's
acceptance of
HPV selfsampling
following an
education
intervention on
cervical cancer
and HPV

Ghana

Cameroon

VIA,
Digital
imaging

HPV
DNA test

Educate: 2week
didactic and
procedural
training for
VIA and
digital
imaging,
ongoing
consultation
Quality:
audit and
feedback for
digital
images via
smartphone
messaging
within 24
hours

Educate: 20
minute
didactic
lecture and
educational
pamphlet
with
instructions
for HPV
selfsamplings

Fidelity: interrater agreement
for VIA between
nurses and
expert physician
Feasibility: VIA
picture quality

Acceptability:
embarrassment,
pain, anxiety,
confidence,
discomfort,
relaxation,
complexity
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(Dim et
al., 2015)

(Firnhabe
r et al.,
2015a)

(Goldhab
er-Fiebert
et al.,
2009)

(Horo et
al., 2012)

Assess
willingness to
pay out-ofpocket for Pap
smear among
HIV positive
women after
provided
information
about cervical
cancer and
screening

Determine
whether a
quality
assurance
program using
digital
cervicography
improved the
performance of
VIA to detect
cervical
intraepithelial
neoplasia grade
2 or worse
(CIN 2+) in
HIV-infected
women

Nigeria

South
Africa

Pap smear

Educate:
individual
counseling
on increased
risk for
cervical
cancer and
Pap smear
protocol and
costs

Acceptability:
willingness to
pay for Pap
smear

VIA,
Digital
Imaging

Educate: 2
week VIA
training
Quality:
audit and
feedback of
VIA cervical
images by
expert
gynecologist
in weekly
QA
meetings

Fidelity:
sensitivity and
specificity of
VIA compared
between nurses’
visual
assessment and
physician digital
image
assessment

Quality:
patient
reminder
system with
community
health
worker
(CHW)
home visits
to encourage
attendance
to follow-up
appointment
s

Costs: total
CHW program
cost, average
cost per women
screened
Penetration:
screening
coverage, total
CHW home
visits completed,
patient
adherence to
appointments

Educate:
individual
counseling,
group

Acceptability:
patient reasons
for loss to
follow-up

Determine the
relationship
between
investment in
community
health worker
(CHW) home
visits and
increased
attendance at
cervical cancer
screening
appointments

South
Africa

Unspecifi
ed
screening,
Colposco
py,
Biopsy

Determine
effect of a
phone based
tracking system

Cote
d’Ivoire

VIA,
VILI,
Colposco
py,

scores.
378 (94.5%)
respondents
were willing to
pay for Pap
smear,
irrespective of
the
cost. Willingne
ss to pay
showed no trend
across age
groups (p=.
148), marital
status groups
(p=. 890),
educational
status groups
(p=. 337), and
parity groups
(p=. .611).
There was
substantial
agreement
between the
VIA real-time
readings of the
nurse and that
of the physician
with digital
cervicography
(k statistic =
0.69). There
was no
statistical
difference
between the
ability of nurses
to detect CIN
2+ at the
beginning and
at the end of the
study.
Adherence
increased from
74% to 90%;
55% to 87%;
48% to 77%;
and 56% to 80%
for 6-, 12-, 24-,
and 36-month
appointments.
The CHW
program cost
R194,018 with
1,576 additional
appointments
attended.
Average perwoman costs
increased by
R14–R47.
The use of a
phone-based
tracking enabled
a significant

Fair

Poor

Good

Poor
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on follow-up
rates

(Huchko
et al.,
2011)

(Kapamb
we et al.,
2013)

Assess the
impact of a
cervical cancer
screening
prevention pilot
project
implemented
into an
established
AIDS program

To evaluate
knowledge
transfer after
training of
traditional
marriage
counselors
(alangizi) to
integrate
cervical cancer
lessons into
their routine
counseling

Biopsy

Kenya

Zambia

VIA,
Colposco
py,
Biopsy,
LEEP

VIA,
Digital
imaging

patient
teaching,
and
educational
pamphlets
Quality:
phone based
patient
reminder
system with
maximum of
3 calls (one
per week)
Educate:
one-week
training for
providers in
VIA,
colposcopy,
and lab
specimen
processing,
individual
patient
counseling
and
community
outreach
Restructure
: increase
lab capacity,
embed in
HIV
program
Quality:
ongoing for
consultation
for program
protocol
through
CCSP
Plan:
develop trust
between
alangizi and
research
team
Educate:
one-day
training on
basic
cervical
cancer
knowledge
for
traditional
marriage
counselors
Restructure
: integrate
cervical
cancer
messaging
into

Penetration:
colposcopy loss
to follow-up
rates

reduction of
women not
attending
medical
consultation
after initial
positive
screening from
36.5% to 19.8%
(p< 10-4).
Reasons for not
following up
include cost,
transportation,
fear and time

Acceptability:
Reasons for
patients refusing
screening,
provider
satisfaction with
training and
program
implementation
Penetration:
VIA screening
coverage,
provider training
coverage
Feasibility:
challenges to
implementing
the program

High coverage
(87%). Reasons
for declining
screening
included partner
support,
menstruation,
and fear. 28
(90%) clinical
officers
underwent
training in VIA
and colposcopy.
The main
challenges
reported were
related to
infrastructure
limitations (lack
of water,
electricity and
supplies; and
long waits in the
clinic) and
perceived
patient barriers

Poor

Feasibility:
perceived
barriers and
facilitators of
integrating
screening

A majority of
the trainees
correctly
associated
cervical
cancer with
HPV (35.6%)
and multiple
sexual
partnerships
(28.9%).

Poor
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(Khozai
m et al.,
2014)

Determine the
challenges and
successes of
integrating a
public-sector
cervical
screening
program into a
large HIV care
system

(Lack et
al., 2005)

Compare two
selfadministered
techniques for
detecting HPV
(tampons and
swabs) with a
clinician
directed
technique
(cervical
cytobrush)

(Ladner
et al.,
2012)

Assess the
effectiveness of
school vs.
clinic based
delivery
models on
HPV vaccine
coverage in 7
different
countries

(LaMont
agne et
al, 2011)

Assess the
effectiveness of
school vs.
clinic based
delivery
models on
HPV vaccine
coverage in 4
different
countries

Kenya

Gambia

Cameroon

Uganda

VIA,
VILI,
Digital
imaging,
Colposco
py,
Biopsy,
Cryothera
py, LEEP

marriage
counseling
Educate:
community
outreach,
mass media
Restructure
: embed in
HIV care
Quality:
patient
reminder
system with
calls and
text
messages for
upcoming
appointment
s

Penetration:
loss to follow-up
rates

HPV
DNA test

Restructure
: selfadministrati
on vs.
physician
collected
swabs

Fidelity:
sensitivity and
specificity
compared
between selfand physician
collected
cervical swabs
Penetration:
screening
coverage

HPV
vaccine

Restructure
: change
service sites
of HPV
vaccination
(school,
clinic, and
mixed
models)

Penetration:
Vaccine
coverage and
adherence

HPV
vaccine

Educate:
community
outreach and
educational
pamphlets
Restructure
: change
service sites
of HPV
vaccination
(health
center,
school, and
integrated
with other
health
program)

Acceptability:
Reasons for
vaccine
acceptance or
refusal
Penetration:
HPV vaccination
coverage

31.5% lost to
follow-up
(27.9%
colposcopy to
biopsy, 49.3%
biopsy to LEEP,
59.6%
colposcopy to
chemo or
hysterectomy)

Selfadministered
swabs showed a
sensitivity of
63.9% and
tampons
showed a
sensitivity of
72.4%
compared to the
cervical
cytobrush as the
gold standard.
The
acceptability of
these two tests
was 97.1% and
84.6%
respectively.
High coverage
(88%) and
adherence
(91%) across
programs. Mixe
d model in both
school and
clinic settings
was most
effective.
High school
coverage
(88.9%) but low
health center
coverage.
Reasons for
accepting the
HPV vaccine
that: (i) it
protects against
cervical cancer;
(ii) it prevents
disease, or (iii)
vaccines are
good. Refusal
was more often
driven by
programmatic

Poor

Poor

Fair

Poor
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considerations
(e.g. school
absenteeism)
than by
opposition to
the vaccine.

(Maree
et al.,
2012)

(Megeva
nd et al.,
1996)

(Mehrotr
a et al.,
2014)

(Michelo
w,
McKee,
&
Hlongwa
ne, 2006)

(Moodley

Determine
whether
cervical
screening
uptake could be
improved when
breast and
cervical
screening are
combined

Determine the
feasibility of
providing a
cervical
screening
facility to the
underprivileged
communities
through an
educational
program and
mobile clinic

Assess the
impact of
enrollment in
an incentive
program on
receipt of 8
preventive care
services
including Pap
smear
Determine if
rapid review of
reportedly
negative
cervical smears
is a useful
internal quality
assurance
modality in an
unscreened
population with
very high rates
of cervical
carcinoma
Demonstrate
the capacity of

South
Africa

South
Africa

VIA

Pap smear
Colposco
py, LEEP

Educate:
one-on-one
patient
counseling
Restructure
: combine
cervical
cancer and
breast
cancer
screenings
Educate:
community
outreach
Restructure
: change
service site
to mobile
clinic with
same day
Pap smear
results and
treatment if
indicated
Quality:
audit and
feedback for
100 of every
300
cytology
slides

Acceptability:
patient reasons
for screening
refusal
Penetration:
VIA screening
coverage

Moderate
coverage (65.4).
Major reason
for refusal was
menstruation.

Good

Penetration:
Loss to followup rates

Loss to followup rates were
much lower for
minimal delay,
mobile delivery
(3%) compared
to longer delay,
clinic delivery
(66%)

Poor

Penetration:
Pap smear
screening
coverage

65.5%
(2,742,268) of
health plan
members
enrolled in the
incentive
program at
some
point. Odds
ratio for receipt
of Pap test is
2.17

Good

Fair

Poor

Pap smear

Finance:
insurance
incentive
program

South
Africa

Pap smear

Quality:
quality
monitoring
system for
randomly
selected Pap
smear slides
by a senior
cytotechnolo
gist

Fidelity:
sensitivity and
specificity

An amended
report was sent
out in 373
(0.59%) of the
62,866 cervical
smears. The
false-negative
proportion for
HSIL and ASCH (combined) in
this study was
5.76%.

South
Africa

HPV
vaccine

Restructure
: integrated

Penetration:
HPV vaccine

High coverage
and adherence

South
Africa
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et al.,
2013)

(Moon et
al., 2013)

(Ogembo
et al.,
2014)

school health
teams to carry
out
vaccinations
within a school
environment

Assess the
feasibility,
successes and
challenges of
integrating a
VIA program
into an existing
HIV program

Inform the
Cameroon
Ministry of
Health of the
acceptability,
feasibility, and
optimal
delivery
strategies for
HPV vaccine.

with cervical
cancer
screening
program for
mothers
Educate:
staff training
in program
policy,
sensitize
school
leadership,
community
outreach

Mozambi
que

Cameroon

VIA,
Cryothera
py, LEEP,
Colposco
py

HPV
vaccine

Educate:
One-week
didactic and
procedural
training in
VIA and
cryotherapy
Restructure
: Change
service sites
– embed in
HIV care

Educate:
community
awareness
campaign
using mass
media,
pamphlets,
and posters
Restructure
: change
delivery
sites (clinic,
school,
community/
mobile),
integrate
with
screening of
mothers
Quality:
patient
reminder
system with
peer
tracking
(school)

coverage and 3
dose adherence

Feasibility:
reasons for delay
in treatment
provision
Penetration:
cryotherapy and
LEEP follow-up
rates
Sustainability:
percentage of
providers still
performing VIA
in 1 year

Feasibility:
vaccines
lost/damaged/ex
pired, adverse
events
Penetration:
vaccine
coverage, refusal
rate, 3 dose
adherence

of the vaccine
was found to be
high: 99.7%,
97.9% and
97.8% for the
first, second and
third doses
respectively.

High and
improved
follow-up rates
between first
(53%) and the
last quarter
(96%)
cryotherapy
same day
coverage rates.
High (88%)
referral followup rates. 0%
physicians and
50% nurses
continued VIA
screening 1 year
after
training. Delays
in treatment
include
equipment theft
and
malfunction.
Total of 6851,
6517 and 5796
girls were
immunized with
the first, second
and third doses
of HPV vaccine,
respectively,
achieving
84.6% full
dosage coverage
of the
adolescents who
received the
first dose. Only
63 of the 19,200
doses received
were lost,
damaged or
expired.
CBCHS
charged a fee of
US$8 per 3dose series only
to those who
were able to
pay. Despite the
fee, 84.6% of

Poor

Poor
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(Quinley
et al.,
2011)

(Ramogo
la-Masire
et al.,
2012)

(Safaeian
et al.,
2007)

(Snyman
et al.,
2015)

Examine the
diagnostic
agreement
between offsite expert
diagnosis using
photographs of
the cervix
(photographic
inspection with
acetic acid,
PIA) and inperson VIA

Determine the
feasibility and
efficiency of
the “see and
treat” approach
using visual
inspection
acetic acid
(VIA) and
enhanced
digital imaging
(EDI) for
cervical cancer
prevention in
HIV-infected
women

Compare
human
papillomavirus
(HPV) DNA
testing between
selfadministered
vaginal swabs
and physicianadministered
cervical swabs

Investigate the
feasibility of
linking HPV
self-testing for
mothers with a
two-dose HPV
vaccination
schedule of
their daughters

Botswana

Botswana

Uganda

South
Africa

HPV
DNA test,
VIA,
Digital
imaging

Quality:
quality
assurance
for digital
cervical
images

Feasibility: rate
of equipment
malfunction
Fidelity: interrater reliability
with expert,
concordance
between VIA
and PIA

VIA,
VILI,
Cryothera
py,
Digital
imaging,

Educate: 3day didactic
teaching and
8 weeks of
procedural
training in
VIA, digital
imaging,
and
cryotherapy
Restructure
: embed in
HIV care
Quality:
audit and
feedback of
cervical
images by
expert
gynecologist
in weekly
quality
control
meetings

Fidelity:
sensitivity,
specificity, interrater reliability
of VIA
assessments
between nurses
and expert
gynecologist
Penetration:
cryotherapy
follow-up rates

HPV
DNA test

Restructure
: selfadministrati
on vs.
physician
collected
swabs

HPV
DNA test,
HPV
vaccine

Educate:
educational
pamphlets
sent home
with
children for
mothers
Restructure
: integrate
HPV DNA

Fidelity:
sensitivity and
specificity
between selfand physiciancollected
samples
Penetration:
screening
coverage

Penetration:
HPV DNA selftesting coverage

the 6,851 girls
who received
the first dose
received all
three doses.
Moderate to
high agreement
(69-100%) with
expert, varied
for each nurse.
High
concordance
(70%) between
PIA and VIA
results. 31
images were
insufficient for
reading.

High agreement
between nurses
and the
gynecologist in
the evaluation
of digital
pictures
(83.3%).
Overall followup 709 of 842
(84.2%)

Compliance
with selfcollected swabs
was >86%;
however, only
51% accepted a
pelvic
examination.
Agreement
among paired
observations
was 92% with a
kappa statistic
of 0.75.
Of the 1,135
self-screen kits
handed out to
eligible girls to
be passed on to
their female
guardians, 160
women
participated in
the self-

Fair

Fair

Good

Poor
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self-sample
kit for
mothers into
vaccination
program for
daughters

(Ting et
al., 2013)

(Tum et
al., 2013)

(Untiet
et al.,
2014)

(Wamai
et al.,
2012)

Compare the
performance of
hrHPV mRNA
testing of
physician- and
self-collected
specimens for
detecting
cytological
high-grade
squamous
intraepithelial
lesions or more
severe
(QHSIL) and
examined risk
factors for
hrHPV mRNA
positivity in
female sex
workers
Determine if a
community
health worker
and education
intervention
could increase
screening
uptake
Test
differences in
performance
between SelfHPV versus
Physician-HPV
and their ability
to detect
abnormal
cytology results

Evaluate the
effectiveness of
a campaign in
sensitizing
parents to HPV
vaccination and
influencing
uptake of
vaccine for
their children

Kenya

South
Africa

Cameroon

Cameroon

HPV
RNA test,
Pap smear

Unspecifi
ed
screening

HPV
DNA test

HPV
vaccine,
VIA,
Digital
imaging

Restructure
: selfadministrati
on vs.
physician
collected
swabs

Education:
health
worker
training,
community
education

Restructure
: selfadministrati
on vs.
physician
collected
swabs

Educate:
Community
outreach,
mass media,
education
program

screening
(14.1%).

Fidelity:
sensitivity and
specificity
compared
between selfand physician
collected
cervical swabs

Acceptability:
patient perceived
value of
community
health worker
Penetration:
screening
coverage

Fidelity:
sensitivity and
specificity
compared
between selfand physician
collected
cervical swabs

Acceptability:
Willingness to
vaccinate,
reasons to
vaccinate or not
Penetration:
VIA screening
coverage,
sensitization
campaign
coverage

Overall
sensitivity of
hrHPV testing
for detecting
QHSIL was
similar in
physiciancollected (86%)
and selfcollected
specimens
(79%). Overall
specificity of
hrHPV mRNA
for QHSIL was
similar in both
physiciancollected (73%)
and selfcollected (75%)
specimens.

Good

Low coverage
(3%). All found
value in health
worker through
informing,
teaching, and
motivating.

Fair

HPV prevalence
was 14.6% and
12.7% for SelfHPV and
Physician-HPV,
respectively
(Cohen's kappa
= 0.74). HPV
positivity by
cytological
diagnosis for
ASC-US+ was
similar with the
two tests
High
willingness to
vaccinate
amongst
parents. Low
coverage
(35.3%) of VIA
screening
amongst
parents. Low
education
program
coverage with
5.9% surveyed
parents learning
about cervical
cancer from

Good

Fair
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program. Top
reasons not to
vaccinate
include
effectiveness
(31.8%), safety
(18.4%),
provider
recommendatio
ns
(17.8%) and
cost (16.6%).

(Were et
al., 2010)

Pilot test and
assess the
feasibility of
integrating VIA
screening into
an existing
maternal child
health and
family planning
program

Kenya

VIA,
VILI

Education:
VIA/VILI
training
Restructure
: change
serviceembed in
maternal
child health
and family
planning

Penetration:
VIA/VILI
screening
coverage and
loss to follow-up

Moderate
coverage and
follow-up. 435
invited - 216
declined 219
accepted. 24 of
40 went for
colposcopy.

Poor
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CHAPTER 3: Methods
Introduction
The overall purpose of this study was to evaluate if providers’ fidelity was
maintained during scale-up of see-and-treat in Botswana. As shown in the literature and
my preliminary fieldwork, there are significant barriers to scale-up of cervical cancer
prevention programs, especially in resource-limited settings (Maseko et al., 2015;
McCree et al., 2015; Randall & Ghebre, 2016). I sought to determine if these barriers
have implications for providers’ fidelity by drawing comparisons between the pilot site
and scaled-up sites for NCCPP. Fidelity is composed of two key aspects, adherence and
competence (Breitenstein et al., 2010; Carroll et al., 2007). Within the context of this
study, adherence referred to how well the nurses followed the NCCPP see-and-treat
algorithm, and competence referred to how well they visually examined the cervix.
Methods for adherence (Aim 1-3) and competence (Aim 4) are presented separately.
Overview
The following study used clinical data that was originally collected as part of
routine patient care and for ongoing monitoring and evaluation of NCCPP during the
scale-up phase from 2014-2015. All women over 18 years were eligible for participation,
but the target population was most at-risk patients (women with HIV and women aged
30-49). Patients were referred for screening in a multitude of ways but most commonly
by primary care offices or HIV clinics. The Botswana-UPenn Partnership (BUP),
appointed by the MOH as implementing partner during scale-up, was responsible for
initially collecting the data. The original IRB approval attained through the University of

Pennsylvania (Penn), University of Botswana, and Botswana’s Ministry of Health was
amended to include the investigator as part of the research team, providing access to the
de-identified data and permission to conduct the following analyses.
Adherence
Specific aims
Aim 1. To determine nurses’ adherence to the NCCPP see-and-treat algorithm
Aim 2. To compare nurses’ adherence between the pilot site and scaled up sites
Hypothesis: Adherence to the algorithm will be significantly higher at the
pilot site compared to the scaled-up sites
Aim 3. To explore reasons why pilot and scaled-up sites differ in adherence rates
Data source
Data consisted of visit-level VIA intake forms, which were included as part of
each patient’s medical chart. Nurses used standardized VIA intake forms (Figure 3.1)
during each patient visit to document information essential for clinical care and program
evaluation. The same form was used among all clinics and included the following
categories of information: demographics, medical/sexual history, pelvic/cervical exam
findings, VIA impression, and treatment/referral action taken by the nurse. All available
forms from the NCCPP scale-up period were included in the study. Therefore, VIA
intake forms from the pilot and scaled-up sites were from the same timeframe of
February 2014 to October 2015.
Data collection
The Botswana-UPenn Partnership (BUP) collected the data through retrospective
chart review. BUP data clerks, who were trained on proper methods for conducting data
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entry using a defined codebook, entered data from each intake form into an excel
spreadsheet. A supervisor periodically checked data entry for completeness and
compiled a report of missing data. Using the report, BUP data clerks were responsible
for rechecking the intake forms and filling in missing values on the spreadsheet where
appropriate. At the end of scale-up, BUP compiled a de-identified data set and provided it
to me via secure data sharing protocols.
Data cleaning
Although the data set was checked for completeness, it was only entered into the
excel spreadsheet once by BUP data clerks with no formal check for accuracy. Therefore,
double digitation was completed by Penn undergraduate research assistants on a random
sample of the data set (n = 67), which was computer generated through Random.org.
Through consensus of the dissertation committee, an a priori determination was made
that an error rate of 5% or greater would require the entire data set to be reentered before
use in statistical analysis. Double digitation of the random sample yielded a satisfactory
error rate of .01%, which did not warrant complete reentry.
After ensuring accuracy of data entry, the binary adherence variable was created
using a coding scheme. The coding scheme, which was validated by clinical and
implementation experts, was developed to translate the NCCPP algorithm into adherence
defined based on patient type. Following the algorithm (Figure 1.1), the coding scheme
determined which combinations of pelvic exam findings, VIA impression, and
treatment/referral action taken by the nurse constituted adherence vs. nonadherence. I
independently conducted coding of the adherence variable, and a statistical team at Penn
completed the quality assurance checks.
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Variables and measures
Patient demographic and clinical characteristics. Medical charts, which are
restricted to information with most relevance to daily clinical practice, were the sole
source of information available for use in this study. Therefore, details regarding
participants’ demographic information was limited. All patient characteristics that were
documented on the VIA intake forms have been included as variables within this study.
Age (AGE), number of children (PARA), and age of sexual debut (SEX_AGE) were
measured as continuous variables. HIV status (HIV), smoking status (SMOKE),
menopausal status (MENO), and previous cervical cancer screening (CC_SRN) were
categorical variables where 1=yes, 2=no, and 3=unknown.
Patient Type. As indicated in the algorithm, treatment and referral plans were
based on pelvic exam findings (normal cervix, abnormal cervix) and VIA impressions
(negative, positive cryo eligible, positive cryo ineligible, uncertain, inadequate,
suspicious for cancer). Fourteen distinct patient types (PT_TYPE) were created based on
these characteristics. Because cell counts/frequencies for several patient types were low
or zero, the 14 patient types were collapsed to create 5 larger categories (PT) to be able to
run the regression analysis. Patient types and rationale for groupings are presented in
Table 3.1.
Adherence. As discussed previously, adherence (ADHERE) is the extent to which
practitioners' behaviors align with the intervention protocol. For the purposes of this
study, the behavior of central interest was the treatment and referral action taken by the
nurse during each patient visit. The intervention protocol was the NCCPP see-and-treat
algorithm. Therefore, adherence was operationalized as the concordance between the
59

algorithm and the nurses’ treatment and referral choice as documented on the VIA intake
form. Adherence was operationalized as a binary variable. If the nurse followed the
algorithm, the clinical encounter was classified as adherent (ADHERE=1). Any actions
that deviated from the algorithm were considered nonadherent (ADHERE=0). As shown
in Table 3.2, adherence was uniquely defined for each patient type. Of note, this measure
was only indicative of provider adherence. It did not reflect patient adherence nor
whether the patient followed through with the nurse’s instruction.
Site. Site (PILOT) was the main exposure variable and referred to the clinic
where each patient visit occurred. There were 6 total clinics. Site was a binary variable
that was categorized as either pilot site (PILOT=1) or scaled-up site (PILOT=0). The
pilot site is located in the capital city of Gaborone. The scaled-up sites are in
Francistown, Lobatse, Mahalapye, Selebi-Phikwe, and Maun.
Visit Date. Visit date referred to the date that each clinical encounter occurred. A
new variable (DATE) was created and calculated as the duration of time (in months)
between the visit date and the scale-up start date of January 2014 (0=Jan 2014, 1= Feb
2014, … 24 = Dec 2015). Another variable (EXPER) was also derived from visit date.
For each encounter, EXPER was measured as the number of months between visit date
and the date of establishment for that site. The date of establishment for the pilot site was
January 2009 and January 2014 for the scaled-up sites. A visit date in February 2014, for
example, would equate to EXPER=1 at the pilot site and EXPER=61 at a scaled-up site.
By accounting for the five-year difference between sites, EXPER was intended to serve
as a proxy for site-specific experience.
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Clinician (CL_NAME). Each VIA intake form for a patient visit was signed by
the nurse that conducted the exam. To preserve confidentiality, each nurse was coded by
a unique ID number. CL_NAME was used to account for within-subject correlation in
the regression analysis.
Sampling strategy, sample size and power analysis
All records from clinic visits at the pilot site and scaled-up sites from 2014 to
2015 were sampled. PASS.14 was used to conduct the power analysis. Based on available
data, sample sizes were 1544 from the pilot site and 5100 from the scaled-up sites. These
sample sizes achieved 80% power to detect a difference between group proportions of 0.0408. Since no estimates were available from the literature or a pilot test, a
conservative estimate of .5000 was used for the estimated proportion. The proportion
from the scaled-up sites (the treatment group) was assumed to be 0.5000 under the null
hypothesis and 0.4592 under the alternative hypothesis. The proportion from the pilot site
(the control group) was 0.5000. The test statistic used was the two-sided Z test with
pooled variance. The significance (alpha) level of the test was targeted at 0.0500.
Data analysis
SAS 9.4 software was used to conduct the following analyses. Descriptive
analysis was conducted for all variables to provide basic summary statistics for the total
clinical encounters. Continuous variables were described by calculating mean, standard
deviation, and range. Categorical variables were described with frequencies and
proportions. Baseline characteristics between pilot and scale-up sites were compared
using two sample t-tests for continuous variables and chi squared X2 or fisher’s exact
tests for categorical variables.
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Aim 1. Limited studies in the literature have provided estimates for providers’
adherence to cervical cancer prevention guidelines. Therefore, I constructed a 2x2
contingency table (cross-tabulation) between adherence (ADHERE) and site (PILOT) to
determine proportions of adherence for the total sample, pilot site, and scaled-up sites.
Aim 2. Through this aim, I evaluated site differences in guideline adherence. To
begin, I used a chi squared X2 test to determine if a statistically significant difference in
proportion of adherence exists between pilot and scaled-up sites. Adding robustness to
the analysis, I also conducted a log-binomial regression modeled using generalized
estimating equations (GEE) to determine if group differences still exist after controlling
for significant covariates. Since clinical encounters are clustered by provider, GEE was
an appropriate choice for this data set and can account for within-subject correlations. To
determine which covariates would be included to create the most parsimonious model, I
used purposeful covariate selection (Bursac, Gauss, Williams, & Hosmer, 2008; Hosmer,
Lemeshow, & Sturdivant, 2013).
Initially, I conducted the multiple regression analysis with logistic regression
given that the outcome variable, adherence, is binary. However, it is suggested that odds
ratios (ORs) do not adequately estimate risk ratios (RRs) when incidence of the outcome
of interest is common (>10%) (Zhang & Yu, 1998). In this study, the incidence of
nonadherence bordered the cutoff at 11.61%. For sensitivity purposes, RRs calculated
by converting the adjusted ORs from logistic regression (using a formula cited in Zhang
1998 (Zhang & Yu, 1998) were compared to the RRs derived directly from log-binomial
regression. The resulting estimates for RRs were vastly different, suggesting ORs is not
an adequate estimation for RRs in this sample. Therefore, only RRs were reported in this
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paper. Further explanation and justification for the methodology used to conduct the
multiple regression analysis with GEE, log-binomial distribution, and purposeful
covariate selection can be found in the statistical appendix.
Aim 3. Two approaches were employed to determine why pilot and scaled-up
sites differed in adherence rates. First, proportions of adherence by patient type for each
site were used to determine: (1) patient type with largest raw count contributing to
nonadherence overall, (2) patient type with the largest proportion of nonadherence, and
(3) patient type with the greatest difference in proportion of nonadherence between
groups. For the 3 identified patient types, frequency tables were created to determine
referral and treatment decisions that were made for nonadherent clinical encounters.
Second, interaction terms were added to the multiple regression model from Aim 2 to
evaluate how patient characteristics associated differently with adherence across sites.
Competence
Specific aim
Aim 4. To determine if competency was sustained 3 years after pilot testing by
comparing nurses’ VIA assessments from the pilot site with that of expert
physicians
Data collection
At the pilot site, quality assurance (QA) meetings were held on a weekly or
biweekly basis. Nurses met with their physician colleagues (1 gynecologist and 2
medical officers) in a conference room and reviewed pictures of each patient’s cervix
taken by digital camera during VIA screening visits. A hand-written, QA book was used
for recordkeeping during the meeting and contained the following information: date,
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patient ID, age, visit type, and VIA result determined by the nurse. If the physicians
disagreed with the nurses’ VIA assessment, the documenter would summarize and note
the physicians’ comments in the QA book. If the physician agreed with the nurse, the
comments section would be left blank. All clinical encounters documented in the QA
book, ranging from August 2014 to June 2015, were included in the analysis.
Demographic and clinical characteristics of patients were recorded in a separate data set
(the registry for initial and follow-up VIA).
Data cleaning
Two researchers transcribed data from the hand-written, QA book into an excel
spreadsheet. To ensure data entry accuracy, both excel sheets were compared for any
discrepancies. Before sensitivity and specificity was calculated from the existing data
set, a variable was created for the expert physicians’ VIA assessments. The nurses’ VIA
assessments were already defined using the following coding scheme: 1=positive,
2=negative, 3=inadequate, 4=uncertain, 5=suspicious for cancer. Using the same coding
scheme, a codebook was developed to categorize physician comments in the QA book for
each patient visit. To obtain further information regarding patient demographics and
clinical characteristics, the QA data set was merged with the registry for initial and
follow-up VIA.
Variables and measures
Competency is defined as the skillfulness demonstrated in the delivery of an
intervention (Breitenstein et al., 2010; Carroll et al., 2007). For the purposes of this
analysis, competency was operationalized using conventional sensitivity and specificity
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metrics. The sensitivity, specificity, negative and positive predictive values of nurses’
VIA assessments were calculated using expert physicians as the gold standard.
Data analysis
Descriptive analysis was conducted for all demographic and medical history
variables to provide basic summary statistics of sampled clinical encounters. Continuous
variables were described by calculating mean, standard deviation, and range. Categorical
variables were described with frequencies and proportions.
Aim 4. Sensitivity was calculated using the proportion of abnormal VIA results
(positive, inadequate, uncertain, suspicious for cancer) that were correctly identified by
the nurses. Specificity was calculated using the proportion of normal VIA results
(negative) that were correctly identified by the nurses. Comparative analysis could not be
conducted for this study aim due to incomplete recordkeeping at the scaled-up clinics. To
conduct a sensitivity analysis, the total number of missing cases was added to each
quadrant of the contingency table to determine a range of possible sensitivity and
specificity rates when accounting for missing data.
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Figures and Tables
Figure 3.1 Initial VIA intake form
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Table 3.1 Patient Types and Categories
Category 1: Normal cervix - VIA negative
VIA Negative: HIV Negative
VIA Negative: HIV Positive
VIA Negative: HIV Unknown
Category 2: Normal cervix - VIA positive
VIA Positive: Cryotherapy Eligible
VIA Positive: Cryotherapy Ineligible
Category 3: Normal cervix - VIA other
VIA Suspicious for Cancer
VIA Inadequate
VIA Uncertain
Category 4: Normal cervix – VIA not performed
VIA Not Performed
VIA Squamous Cell Junction (SCJ) Not Seen
Category 5: Abnormal cervix
Heavy Menses
Abnormal Discharge
Cancer
Other
Note: To run the multiple regression analysis, the 14 patient types were categorized into 5
larger groups. Categories 1-4 pertain to patients with normal cervixes and were grouped
by VIA impression. All patients with abnormal cervixes were aggregated in Category 5.
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Table 3.2 Adherence Defined by Patient Type
Patient Type

Adherence Definition

Normal Cervix
VIA Negative: HIV Negative

No treatment - 5 year follow-up

VIA Negative: HIV Positive

No treatment - 3 year follow-up

VIA Negative: HIV Unknown

No treatment - 3 year follow-up

VIA Positive: Cryo Eligible

Cryotherapy - 1 year follow-up

VIA Positive: Cryo Ineligible

No cryotherapy, Refer

VIA Suspicious for Cancer

Refer

VIA Inadequate

Refer

VIA Uncertain

Refer

VIA Not Performed

N/a

VIA SCJ Not Seen

Refer

Abnormal Cervix
Heavy Menses
Abnormal Discharge

Reschedule VIA
Treat with Antibiotics, Reschedule VIA

Cancer

Refer

Other

Refer

Note: As shown, adherence was uniquely defined for each patient type. This table shows
the correct treatment and referral action that a nurse should take to be considered
adherent to the NCCPP see-and-treat algorithm shown in Figure 1.1.
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CHAPTER 4: Results
Adherence
Summary of Baseline Demographic and Clinical Characteristics
As part of Botswana’s National Cervical Cancer Prevention Program, 6644 total
clinical encounters from 44 clinicians took place between February 2014 and October
2015. 387 encounters were second visits for the same patient. Therefore, the sample was
from 6627 unique patients. Most patient visits (n=5100, 76.8%) were conducted at the
scaled-up sites. The remaining 23.2% (n=1544) occurred at the pilot site in Gaborone.
Of the scaled-up sites, 1605 (31.47%) encounters were in Francistown, 821 (16.10%) in
Lobatse, 1092 (21.41%) in Mahalapye, 1091 (21.39%) in Selebi-Phikwe, and 491
(9.63%) in Maun.
Baseline demographic and clinical characteristics of the total encounters are
summarized in Table 4.1. Women in the study sample were on average aged 36.37 with
2.25 children and sexually debuted at age 18.89. Most women had not reached
menopause (98.48%), were non-smokers (98.28%), and had not been previously screened
for cervical cancer (52.42%). For those who had been previously screened, 3085
(98.34%) were screened with Pap smear, 24 (.77%) with VIA, and 28 (.89%) could not
recall the screening modality. 50.86% of the women were HIV positive. This rate is
nearly twice the population prevalence of 25.2% estimated in 2012, with women bearing
a disproportionate burden compared to their male counterparts. If only considering
women with known HIV status, the prevalence rate increases to 55.87%. The high HIV
rate in this sample was partly due to the Pink Ribbon Red Ribbon (PRRR) funding source
for NCCPP. PRRR uses resources from already existing HIV treatment infrastructure
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and promotes screenings within this population given their increased risk of developing
cervical cancer. Although screenings were open to all women, regardless of HIV status,
women with HIV were largely targeted due to the programs’ infrastructure.
Comparisons between samples from the pilot site and scaled-up sites show
statistically significant differences in all baseline characteristics except menopause
(p=.7244) and smoking status (p=.7339). Although statistically significant, observed
differences between groups for several variables (age, number of children, age of sexual
debut) are quite small and have limited clinical significance. Compared to the pilot site,
women from the scaled-up sites were older (p<.0001), had more children (p<.0001), and
sexually debuted at an earlier age (p=.0019). Scaled-up sites also had a larger proportion
of women with HIV (p<.0001) and women who had been previously screened for
cervical cancer (p<.0001).
Visit Date. Figure 4.1 shows the frequency of clinical encounters by month of the
scale-up period. As graphed, the distributions differ between pilot and scale-up sites.
The volume of patient visits at the scaled-up sites increased steadily over time, which is
consistent with expectations. As the sites became increasingly organized, they became
more capable of carrying out VIA exams and increased their patient intake accordingly.
To contrast, the pilot site maintained more consistency over time with the number of
patient visits conducted each month. Frequency of visits decreased dramatically at the
end of scale-up for both sites. This reduction is likely due to the abrupt end of PRRR
funding and uncertainty of the programs’ survival.
Age. Figure 4.2 shows the frequency of clinical encounters by age. Although
women of all ages were eligible to participate in NCCPP, 5594 (84.20%) of the total
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encounters were within the targeted age range of 30-49. 952 women (14.33%) were
younger than 30, and 98 (1.48%) were 50 years or older. 78.69% of women at pilot site
were in the target age range compared to 85.86% at scaled-up sites.
HIV Status. Figure 4.3 shows proportions of HIV status for each site, which
varied significantly between sites (p<.0001). Pairwise comparisons revealed that sites
differed most regarding HIV unknown status. Scaled-up sites had nearly 2.3 times more
women with unknown HIV status. The proportions of HIV negative and positive patients
were more similar between sites (47.54% vs. 51.86% and 36.37% vs. 41.35%,
respectively).
Patient Type. Figure 4.4 shows the proportions of patient type within each site,
which also varied significantly (p<.0001). For both sites, the patient types with the largest
proportions were VIA negative and VIA positive. However, the pilot site had larger
proportion of VIA positive women compared with the scaled-up sites.
Providers’ Adherence to NCCPP See-and-Treat Algorithm (Aim 1, Aim 2)
Overall, provider adherence to the NCCPP algorithm was high (Table 4.2). Of the
6580 total clinical encounters, 88.39% (n=5816) documented the correct treatment and
referral as indicated in the NCCPP algorithm. 11.61% (n=764) of encounters deviated
from guideline recommendations. Due to missing data, determinations of adherence vs.
nonadherence could not be made for 64 encounters.
Adherence by site. Table 4.2 shows the proportions of adherence and
nonadherence for the total sample, pilot site, and scaled-up sites. Although overall
adherence was high, rates of adherence varied significantly between pilot and scaled-up
sites. Contrary to the stated hypothesis, the pilot site was less adherent to the algorithm
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than the scaled-up sites. 90.86% of encounters from the scaled-up sites were adherent
compared to 80.20% at the pilot site. There was an approximately 10% difference
between sites, which is shown to be statistically significant by the chi-squared statistic
(p<.0001).
At the univariate level of analysis (Table 4.3), the association between site and
adherence was only marginally significant (p=.1146). However, site was the exposure
variable of primary interest and met criteria for inclusion (p<.25) in the initial multiple
regression model according to the purposeful covariate selection process. Previously
screened (p=.3189), smoking status (p=.9341), and visit date (p=.9595) were not
significantly associated with adherence. Age (p=.0050), number of children (p=.0775),
age of sexual debut (p=.1246), menopausal status (p=.2346), HIV status (p=.0004),
patient type (p<.0001), and experience (p=.2321) were significant at the p<.25 level and
were also fitted in the initial model. Once entered into the model, variables needed to
meet the p<.10 parameter to remain in the model. Age, age of sexual debut, and
menopausal status were no longer significant. However, age and menopausal status
created >20% change in the coefficient estimate for site and were included in the model
as important confounders. Age of sexual debut was excluded. Due to severe
multicollinearity, experience was also excluded. Experience was highly correlated with
site, which distorted the coefficient estimate for that variable. Given that site was the
main exposure variable, it was important to retain precise coefficient estimates.
Table 4.4 shows the multiple regression model results after conducting purposeful
covariate selection. Without adjustments, scaled-up sites were 1.0483 times as likely to
be adherent to the guidelines compared to the pilot site (p=.1146). When controlling for
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significant covariates, however, scaled-up sites were .9845 times as likely to be adherent
to the algorithm (p=.2205).
Adherence over time. Overall, adherence decreased over time (Figure 4.5).
Scaled-up sites maintained a more consistent rate of adherence. However, the last 5
months was marked by a dramatic decline. To contrast, the pilot site remained more
consistent throughout, with a slight decrease observed over time. Although the scaled-up
sites began with a much higher rate of adherence than the pilot site, the proportion of
adherence for both sites interestingly converged towards the end of scale-up to
approximately 75%.
Adherence by patient-level characteristics. From the univariate analysis, there
was strong statistical evidence of an association between providers’ adherence and
patients’ age (p=.0050), number of children (.0775), HIV status (p=.0004), and patient
type (p<.0001). Figure 4.6 shows adherence increases with older age. Among the
subgroups for HIV status and patient type, encounters with HIV negative patients and
VIA positive patients were most likely to be adherent. Age of sexual debut (p=.1246),
menopausal status (p=.2346) and previously screened (p=.3189) were marginally
associated with adherence. There was no statistical evidence of an association between
adherence and smoking status (p=.9341), or visit date (.9595).
Main Drivers of Nonadherence (Aim 3)
Patient types. Table 4.5 shows nonadherence by patient type for the pilot site,
scaled-up sites, and total sample. Table 4.6 shows proportions of adherence by patient
type and the difference in those proportions between sites. Tables 4.5 and 4.6 were used
to identify patient types with: (1) the largest raw count contributing to overall
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nonadherence, (2) the largest proportion of nonadherence, and (3) the greatest difference
in proportions of nonadherence between pilot and scaled-up sites. Reasons for
nonadherence have been summarized for these three patient types below:
•

VIA negative: HIV negative. According to the algorithm, these patients
should not be treated and should be recommended to follow-up with screening
in 5 years. A total of 144 clinical encounters from this patient type were
nonadherent. Reasons for nonadherence included either the nurse
recommending the wrong follow-up time (n=84) or not specifying a follow-up
time at all (n=56) for these patients. Four encounters could not be classified
due to missing data. Misspecifications for follow-up times were 3 years
(n=78), 1 year (n=4), 6 years (n=1), or 15 years (n=1). Among the encounters
that did not specify a follow-up time, many of those patients (n=27) had been
treated with cryotherapy for ectropy. Cryo for ectropy is a common treatment
for VIA negative patients, but is not mentioned in the algorithm.

•

VIA negative: HIV unknown. Patients in this category should not be treated
and should follow-up for screening in 3 years. The follow-up timing was not
specified in the algorithm but was confirmed to be taught during training by
the implementing team. A total of 163 clinical encounters for this patient type
were nonadherent. Similar to VIA Negative HIV negative patients, the nurse
either recommended the wrong follow-up time (n=148) or did not specify a
follow-up time at all (n=15). All encounters that specified the wrong followup recommended patients to return in 5 years rather than 3. Six of the 15
encounters that did not specify follow-up were treated with cryo for ectropy.
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•

VIA not performed. Nurses should proceed with performing VIA if the
patients have a normal cervical exam. Contraindications for VIA include
discharge consistent with infection, heavy menses, or suspicion for cancer and
would classify the encounter as abnormal cervix. This category included 178
patients who had a normal cervix, but the nurse did not perform VIA. Instead,
90 were deferred, 43 referred, 24 treated with cryotherapy, and 21 had no
specified action.

Patient-level characteristics. Using purposeful covariate selection, significant
interaction terms were added to the multiple regression model from Aim 2. Site
interacted with HIV status (p<.0001) and patient type (p=.0025) was significant at the
p<.10 level and, therefore, included in the model shown in Table 4.7. Adjusted risks for
HIV status and patient type by site are shown in Figures 4.7 and 4.8, respectively.
Regarding HIV status, adjusted risk is similar between sites for HIV negative and HIV
positive patients. However, there are site differences for HIV unknown status, with
providers at the pilot site being less likely to adhere. Regarding patient types, the overall
trends are similar between sites. The pilot site is consistently less likely to adhere for all
patient types, except VIA not performed.
Competence
There were 1633 clinical encounters included in this study aim with available
demographic and clinical information. Baseline characteristics of these encounters are
summarized in Table 4.8. Overall, the study sample consisted of women on average aged
36.9 with 2.03 children. Most women had not reached menopause (97.67%) and were
non-smokers (98.78%). Approximately 67% of women were HIV positive. When only
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considering women with known HIV status, the prevalence rate increased to 74.72%,
nearly three times the estimated population prevalence of 25.2%.
When comparing VIA assessments between nurses and expert physicians (Table
4.9), the analysis yielded a sensitivity rate of 75.43% (95% CI, 71.27%-79.26%) and
specificity rate of 92.40% (95% CI, 90.62%-93.92%). The positive predictive value was
81.52% (95% CI, 78.03-84.57%), and the negative predictive value was 89.42%(87.8190.84%). Due to missing data, 113 encounters were not included within these
calculations.
For sensitivity purposes, ranges of sensitivity and specificity were estimated when
the 113 missing cases were accounted. Sensitivity increased to 80.21% (76.73-83.37%)
or decreased to 60.76%% (56.65-64.75%) when missing cases were included in the true
positive or false negative counts, respectively. Specificity increased to 93.13% (91.5394.52%) or decreased to 83.43% (81.17-85.52%) when missing cases were added to the
true negative or false positive counts, respectively.
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Figures and Tables
Figure 4.1 Frequency of Clinical Encounters by Month

Total Sample (N=6642)

Pilot Site (N=1544)

77

Scaled-up Sites (N=5098)

Note: Frequencies were calculated as number of clinical encounters. Dates were
calculated as months since the start of scale-up (January 2014) and are numbered as
follows: 1 = February 2014, 2= March 2014… 20 = October 2015).
*missing 2 from scaled-up sites
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Figure 4.2 Frequency of Clinical Encounters by Age

Total Sample (N=6644)

Pilot Site (N=1544)

79

Scaled-up Sites (N=5100)

Note: Frequencies were calculated as number of clinical encounters. Age refers to
patients’ age at time of clinical visit.
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Figure 4.3 Proportion of HIV status by Site
Pilot Site (N=1544)

HIV unknown
16.19%

HIV negative
47.54%
HIV positive
36.27%

Scaled-up Sites (N=5100)
HIV unknown
6.78%

HIV positive
41.35%

HIV negative
51.86%
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Figure 4.4 Proportion of Patient Types by Site
Pilot Site (N=1525)
Abnormal
cervix
8.72%

VIA not
performed
5.38%
VIA other
2.10%

VIA positive
24.33%

VIA negative
59.48%

Scaled-Up Sites (N=5055)

VIA not
performed
5%

Abnormal
cervix
6%

VIA other
3%

VIA negative
47%
VIA positive
39%

*missing 19 from pilot sites and 45 from scaled-up sites
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Figure 4.5 LOWESS Plot of Adherence and Date
Total Sample (N=6580)

Pilot Site (N=1525)

83

Scaled-Up Sites (N=5055)

Note: Dates were calculated as months since the start of scale-up (January 2014) and are
numbered as follows: 1 = February 2014, 2= March 2014… 20 = October 2015).
Proportion of adherence was estimated using locally weighted scatter plot smoothing
(LOWESS).
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Figure 4.6 LOWESS Plot of Adherence and Age
Total Sample (N=6580)

Pilot Site (N=1525)

85

Scaled-Up Sites (N=5055)

Note: Age refers to patients’ age at time of clinical visit. Proportion of adherence was
estimated using locally weighted scatter plot smoothing (LOWESS).
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Figure 4.7 Adjusted Risk for HIV status by Site (N=6580)

Adjusted Risk by HIV Status and Site
1
0.9
0.8
0.7
0.6
0.5
0.4

0.76

0.77

0.3

0.73

0.75

0.67
0.43

0.2
0.1
0
Negative

Positive
Pilot Site

Unknown

Scaled-up Sites

Note: The following estimates have been calculated using multiple regression analysis
with interactions terms. The analysis was conducted using log-binomial regression
modelled with generalized estimating equations (GEE). Exchangeable correlation
structure and clustering by provider were specified in the GEE model. Purposeful
covariate selection was used to determined which significant covariates and interaction
terms would be included in the final model. The adjusted risks shown in this graph are
from the interaction term, site*HIV status, and have been controlled for all other
significant covariates (site, age, number of children, menopausal status, HIV status,
patient type, site*patient type). Error bars are included on the graph to specify 95%
confidence intervals.
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Figure 4.8 Adjusted Risk for Patient Type by Site (N=6580)

Adjusted Risk by Patient Type and Site
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0

0.89
0.73

0.77

0.89

0.85

0.85
0.70

0.57
0.40 0.36

VIA Negative

VIA Positive

VIA Other

Pilot Sites

VIA Not
Performed

Abnormal
Cervix

Scaled-up Sites

Note: The following estimates have been calculated using multiple regression analysis
with interactions terms. The analysis was conducted using log-binomial regression
modelled with generalized estimating equations (GEE). Exchangeable correlation
structure and clustering by provider were specified in the GEE model. Purposeful
covariate selection was used to determined which significant covariates and interaction
terms would be included in the final model. The adjusted risks shown in this graph are
from the interaction term, site*patient type, and have been controlled for all other
significant covariates (site, age, number of children, menopausal status, HIV status,
patient type, site*HIV status). Error bars are included on the graph to specify 95%
confidence intervals.
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Table 4.1 Baseline Demographic and Clinical Characteristics for Total Clinical
Encounters – Adherence (N=6644)
Total Sample
(n=6644)

Characteristics

Pilot Site
(n=1544)

Scaled-up
Sites
(n=5100)

T test or
Chi
Squared
Test

n or
Mean
(SD)

Range
or %

n or
Range
Mean
or %
(SD)

n or
Mean
(SD)

Range
or %

Age

36.27
(6.44)

17-59

35.52
(6.44)

20-56

36.49
(6.42)

17-59

p<.0001

Number of
Children

2.25
(1.5)

0-12

1.94
(1.39)

0-10

2.34
(1.52)

0-12

p<.0001

Age of Sexual
Debut
*missing 5

18.89
(2.62)

5-45

19.09
(2.82)

12-4

18.84
(2.54)

5-45

p=.0019

101
6539

1.52%
98.48%

22
1522

1.42%
98.58%

79
5017

1.55%
98.45%

p=.7244

3379
2669
596

50.86%
40.17%
8.97%

734
560
250

47.54%
36.27%
16.19%

2645
2109
346

51.86%
41.35%
6.78%

114
6523

1.72%
98.28%

25
1519

1.62%
98.38%

89
5004

1.75%
98.25%

3137
3474
16

47.34%
52.42%
0.24%

576
961
7

37.31%
62.24%
0.45%

2561
2513
9

50.38%
49.44%
0.18%

Menopausal
Yes
No
*missing 4
HIV
Positive
Negative
Unknown
Smoker
Yes
No
*missing 7
Previously
Screened
Yes
No
Unknown
*missing 17

p<.0001

p=.7339

p<.0001
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Patient types
VIA negative
VIA positive
VIA other
VIA not perfor
Abnormal cervi
*missing 64

3293
2327
179
317
464

50.5%
35.36%
2.72%
4.82%
7.05%

907
371
32
82
133

59.48%
24.33%
2.10%
5.38%
8.72%

2386
1956
147
235
331

47.20%
38.69%
2.91%
4.65%
6.55%

Experience
(months since
clinic was
established)
*missing 2

25.96
(24.49)

1-81

12.68
(3.87)

1-20

69.83
(4.76)

61-81

p<.0001

Visit Date
(months since
beginning of
scale-up)
*missing 2

12.01
(4.27)

1-21

9.83
(4.76)

1-21

12.68
(3.87)

1-20

p<.0001

p<.0001

Note: Continuous variables (age, number of children, age of sexual debut, visit date,
experience) were described by calculating mean, standard deviation (SD), and range.
Categorical variables (HIV status, smoking status, menopausal status, and previous
cervical cancer screening) were described with frequencies (n) and proportions (%).
Baseline characteristics between pilot and scale-up sites were compared using two
sample t-tests for continuous variables and chi squared X2 or fisher’s exact tests for
categorical variables.
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Table 4.2 Contingency Table (Cross-tabulation) of Adherence by Site (N=6580)

Nonadherence

Adherence

Pilot site
(n=1525)

302
(19.80%)

1223
(80.20%)

Scale-up sites
(n=5055)

462
(9.14%)

4593
(90.86%)

Total sample
(n=6580)

764
(11.61%)

5816
(88.39%)

*missing 64

Chi X2 Square = 127.8704
p<.0001
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Table 4.3 Results from Univariate Analysis – Estimating Adherence to NCCPP See-andTreat Algorithms Using Log Binomial Regression Modeled with Generalized Estimating
Equations (N=6580)
Variable
PILOT
Scaled-up site
Pilot site
AGE
Patient age
PARA
Number of children
SEX_AGE
Age of debut
MENO
Yes
No
SMOKE
Yes
No
HIV
Negative
Positive
Unknown
CC_SRN
Yes
No
Unknown
PT
Normal: VIA negative
Normal: VIA positive
Normal: VIA other
Normal: VIA not perf
Abnormal cervix
DATE
Visit date
DATESQ

Risk Ratio

95% CI
Lower

95% CI
Upper

1.0483
ref

0.9887
.

1.1115
.

1.0023

1.0007

1.0039

1.0070

1.0008

1.0149

0.9981

0.9958

1.0005

0.9513
ref

0.8761
.

1.0329
.

1.0034
ref

0.9259
.

1.0874
.

1.3441
1.3003
ref

1.1344
1.1018
.

1.5927
1.5345
.

1.0018
0.9896
ref

0.8284
0.8183
.

1.2115
1.1967
.

1.0116
1.0802
0.9570
0.4524
ref

0.9557
1.0176
0.8532
0.3350
.

1.0708
1.1467
1.0734
0.6110
.

0.9999

0.9945

1.0052

1.0000

0.9997

1.0002

EXPER
Experience

Wald Statistic
p value
0.1146
0.1146
.
0.0050
0.0050
0.0775
0.0775
0.1246
0.1246
0.2346
0.2346
.
0.9341
0.9341
.
0.0004
0.0006
0.0019
.
0.3189
0.9849
0.9140
.
<.0001
0.6905
0.0114
0.4529
<.0001
.
0.9595
0.9595
0.7247
0.7247
0.2321

0.9993

0.9981

1.0005

0.2321
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Note: Risk ratios for each covariate were calculated using log-binomial regression
modelled with generalized estimating equations (GEE). The regression analysis modelled
the probability that ADHERE=1 (adherence). Exchangeable correlation structure and
clustering by provider were specified in the GEE model. In addition to risk ratios, 95%
confidence intervals and Wald statistics are reported.
*bold text = Wald statistic for covariate
regular text = p-value for subcategory of each covariate.
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Table 4.4 Results from Multiple Regression Analysis - Estimating Adherence to NCCPP
See-and-Treat Algorithms Using Log Binomial Regression Modeled with Generalized
Estimating Equations (N=6580)
Variable

Risk
Ratio

95% CI
Lower

95% CI
Upper

0.6624

0.5488

0.7995

0.9845
ref

0.9603
.

1.0094
.

1.0010

0.9996

1.0024

0.9959

0.9918

1.0000

0.9663
ref

0.8907
.

1.0482
.

1.3315
1.2969
ref

1.1345
1.1037
.

1.5628
1.5241
.

1.0446
1.0648
0.9696
0.4559
ref

0.9982
1.0048
0.8760
0.3317
.

1.0930
1.1284
1.0732
0.6267
.

Wald Statistic
p value

INTERCEPT
PILOT
Scaled-up site
Pilot site
AGE
Patient age
PARA
Number of children
MENO
Yes
No
HIV
Negative
Positive
Unknown
PT
Normal: VIA negative
Normal: VIA positive
Normal: VIA other
Normal: VIA not perf
Abnormal cervix

<.0001
0.2205
0.2205
.
0.1508
0.1508
.0502
.0502
.4091
.4091
.
.0002
0.0005
0.0016
.
<.0001
0.0597
0.0339
0.5509
<.0001
.

Note: Risk ratios were calculated using log-binomial regression modelled with
generalized estimating equations (GEE). The regression analysis modelled the probability
that ADHERE=1 (adherence). Exchangeable correlation structure and clustering by
provider were specified in the GEE model. Purposeful covariate selection was used to
determine which significant covariates would be included in the final regression model.
In addition to risk ratios controlling for all other covariates, 95% confidence intervals and
Wald statistics are reported.
*bold text = Wald statistic for covariate
regular text = p-value for subcategory of each covariate.
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Table 4.5 Nonadherence by Patient Type compared between Pilot Site and Scaled-up
Sites (N=764)
Nonadherence
Patient Type
1
VIA negative: HIV negative
2
VIA negative: HIV positive
3
VIA negative: HIV unknown
4
VIA positive: CRYO eligible
5
VIA positive: CRYO ineligible
6
VIA suspicious for cancer
7
VIA uncertain
8
VIA inadequate
9
VIA not performed
10
VIA performed: SCJ not seen
11
Abnormal Cervix: Heavy
Menses

Scale-up Sites
(n=462)

Pilot Site
(n=302)

All
(n=764)

93

51

144

(20.13%)

(16.89%)

(18.85%)

31

33

64

(6.71%)

(10.93%

(8.83%)

49

114

163

(10.61%)

(37.75%)

(21.34%)

55

11

66

(11.90%)

(3.64%)

(8.64%)

28

11

39

(6.06%)

(3.64%)

(5.10%)

0

1

1

(0.00%)

(0.33%)

(0.13%)

18

9

27

(3.90%)

(2.98%)

(3.53%)

0

1

1

(0.00%)

(0.33%)

(0.13%)

139

39

178

(30.09%)

(12.91%)

23.30%

15

8

23

(3.25%)

(2.65%)

(3.01%)

0

0

0

(0.00%)

(0.00%)

(0.00%)
95

12
Abnormal cervix: Discharge
13
Abnormal cervix: Cancer
14
Abnormal cervix: Other

23

6

29

(4.98%)

(1.99%)

(3.80%)

0

0

0

(0.00%)

(0.00%)

(0.00%)

11

18

29

(2.38%)

(5.96%)

(3.80%)

Note: For each patient type, proportions of nonadherence are reported at the pilot site,
scaled-up sites, and all sites.
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Table 4.6 Proportions of Adherence and Nonadherence by Patient Type
Compared between Pilot Site and Scaled-Up Sites (N=6580)

Scaled - Up Sites
(N=5055)

Pilot Sites
(N=1525)

All
N= (6580)

D
Adhere
nce %

ChiSq
or
Fisher’s
Exact
Test

Patient
Type

Adheren
ce

Nonadhe
rence

Adheren
ce

Nonadhe
rence

Adheren
ce

Nonadhe
rence

1
VIA
NEG:
HIV
NEG

1029
(91.71%)

93
(8.29%)

303
(85.59%)

51
(14.41%)

1332
(90.24%)

144
(9.76%)

6.12%

p=.0007

2
VIA
NEG:
HIV POS

1090
(97.23%)

31
(2.77%)

355
(91.49%)

33
(8.51%)

1445
(95.76%)

64
(4.24%)

5.74%

p<.0001

3
VIA
NEG:
HIV
UNK

94
(65.73%)

49
(34.27%)

51
(30.91%)

114
(69.09%)

145
(47.08%)

163
(52.92%)

34.82%

p<.0001

4
VIA
POS:
CRYO
ELI

296
(84.33%)

55
(15.67%)

122
(91.73%)

11
(8.27%)

418
(86.36%)

66
(13.64%)

7.4%

p=.0342

5
VIA
POS:
CRYO
INELI

1577
(98.26%)

28
(1.74%)

227
(95.38%)

11
(4.62%)

1804
(97.88%)

39
(2.12%)

2.88%

p=.0040

6
VIA SUS
CAN

30
(88.24%)

0
(0.00%)

3
(75%)

1
(25%)

33
(97.06%)

1
(2.94%)

13.24%

7
VIA
UNCER
TAIN

95
(84.07%)

18
(15.93%)

12
(57.14%)

9
(42.86%)

107
(79.85%)

27
(20.15%)

26.93%

p=.1176

p=.0141
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8
VIA
INADEQ
UATE

4
(100%)

0
(0.00%)

6
(85.71%)

1
(14.29%)

10
(90.91%)

1
(9.09%)

14.29%

p=1.0

9
VIA
NOT
PERFOR
MED

0
(0.00%)

139
(100%)

0
(0.00%)

39
(100%)

0
(0.00%)

178
(100%)

0%

--

10
VIA
PERFOR
MED:
SCJ
NOT
SEEN

81
(84.38%)

15
(15.63%)

35
(81.49%)

8
(18.60%)

116
(83.45%)

23
(16.55%)

2.89%

p=.6621

11
ABNOR
MAL
CERVIX
:
MENSES

3
(100%)

0
(0.00%)

0
(0.00%)

0
(0.00%)

3
(100%)

0
(0.00%)

0%

--

12
ABNOR
MAL
CERVIX
:
DISCHA
RGE

102
(81.60%)

23
(18.40%)

64
(91.43%)

6
(8.57%)

166
(85.13%)

29
(14.87%)

9.83%

p=.0643

13
ABNOR
MAL
CERVIX
:
CANCE
R

6
(100%)

0
(0.00%)

6
(100%)

0
(0.00%)

12
(100%)

0
(0.00%)

0%

--

14
ABNOR
MAL
CERVIX
:
OTHER

186
(94.42%)

11
(5.58%)

39
(68.42%)

18
(31.58%)

225
(88.58%)

29
(11.42%)

26%

p<.0001

Note: For each patient type, proportions of adherence and nonadherence are reported at
the pilot site, scaled-up sites, and all sites. Proportions of adherence between pilot and
scale-up sites were compared using chi squared X2 or fisher’s exact tests and p-values are
reported for each patient type. Difference in proportions of adherence (D Adherence %)
between pilot and scaled-up sites were also calculated for each patient type.
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Table 4.7. Results from Multiple Regression Analysis with Interaction Terms Estimating Adherence to NCCPP See-and-Treat Algorithms Using Log Binomial
Regression Modeled with Generalized Estimating Equations (N=6580)
Variable
INTERCEPT
PILOT
Scaled-up site
Pilot site
AGE
Patient age
PARA
# of children
MENO
Yes
No
HIV
Negative
Positive
Unknown
PT
Normal: VIA negative
Normal: VIA positive
Normal: VIA other
Normal: VIA not perf
Abnormal cervix
PILOT*HIV
Scaled-up site
Negative
Positive
Unknown
Pilot site
PILOT*PT
Scaled-up site
Normal: VIA negati
Normal: VIA positiv
Normal: VIA other
Normal: VIA not pe
Abnormal cervix
Pilot Site

Risk
Ratio

95%
CI
Lower

95% CI
Upper

Wald

0.4816

0.3980

0.5827

<.0001
.0027
<.0001
.
.4336
.4336
.0917
.0917
.4442
.4442
.
<.0001
<.0001
0.0004
.
<.0001
0.2920
0.0265
0.0310
0.0065
.
<.0001

1.6219
ref

1.3194
.

1.9935
.

1.0005

0.9992

1.0019

0.9968

0.9930

1.0005

0.9708
ref

0.9001
.

1.0473
.

1.7798
1.7011
ref

1.4013
1.2705
.

2.2605
2.2780
.

1.0526
1.1109
0.8258
0.5690
ref

0.9569
1.0124
0.6941
0.3790
.

1.1581
1.2191
0.9827
0.8544
.

0.6471
0.6621
ref
ref

0.5033
0.4896
.
.

0.8321
0.8954
.
.

0.0007
0.0074
.
.
0.0025

0.9944
0.9475
1.2137
0.7471
ref
ref

0.8879
0.8354
0.9833
0.4406
.
.

1.1137
1.0748
1.4980
1.2672
.
.

0.9224
0.4018
0.0713
0.2795
.
.
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Note: Risk ratios were calculated using log-binomial regression modelled with
generalized estimating equations (GEE). The regression analysis modelled the probability
that ADHERE=1 (adherence). Exchangeable correlation structure and clustering by
provider were specified in the GEE model. Purposeful covariate selection was used to
determine which significant covariates and interactions terms would be included in the
final regression model. In addition to risk ratios controlling for all other covariates, 95%
confidence intervals and Wald statistics are reported.
*bold text = Wald statistic for covariate
regular text = p-value for subcategory of each covariate.
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Table 4.8 Summary of Patient Characteristics for Total Clinical Encounters Competence (N=1633)
Total Sample
(n=1633)
Characteristics

N or Mean(SD)

Range or %

Age

36.90 (6.27)

20-57

Number of Children

2.03 (1.40)

0-10

Menopausal
Yes
No

38
1595

2.33%
97.67%

HIV
Positive
Negative
Unknown

1094
370
169

66.99%
22.66%
10.35%

Smoker
Yes
No

20
1613

1.22%
98.78%

Visit Type
VIA initial
VIA follow-up

938
695

57.44%
42.56%

1101
330
94
17
2

71.31%
21.37%
6.08%
1.10%
0.13%

Nurse VIA result
Negative
Positive
Inadequate
Uncertain
Suspicious for Cancer
*missing 89

Note: Continuous variables (age, number of children) were described by calculating
mean, standard deviation (SD), and range. Categorical variables (menopausal status, HIV
status, smoking status, visit type, nurse VIA result) were described with frequencies (n)
and proportions (%).
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Table 4.9 Nurses’ VIA assessments compared to Expert Physicians (N= 1520)
Physician
Abnormal

Normal

Total

353

80

433

115

972

1087

468

1052

1520

N
u Abnormal
r
s
e
Normal
Total
*missing 113
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CHAPTER 5: Discussion and conclusion to the body of work
Through this dissertation, I have made an effort to enter cervical cancer
prevention in low resource settings into the implementation science conversation. It is
well known in the field that a significant research-to-practice gap exists in which the most
vulnerable, at-risk women are not receiving preventive services. Yet, I have found
through a systematic literature review that very few studies have explicitly and rigorously
researched the implementation of cervical cancer prevention programs in these settings.
The overall purpose of this study has been to comprehensively assess providers’
fidelity to the see-and-treat algorithms of Botswana’s National Cervical Cancer
Prevention Program. Fidelity is only one of the seven distinct implementation outcomes
defined by Proctor et al (2011) (Proctor et al., 2011), a seminal work in implementation
science, but it is a key metric for evaluating scale-up. To achieve population-level
reductions in cervical cancer, the goal of scale-up is to implement health innovations with
high fidelity and achieve desired coverage.
Attempts have been made in the past to scale-up Pap testing in resource-limited
settings. However, many countries have had limited success due to implementation
barriers and resource constraints. See-and-treat is a simpler, alternative method that was
developed to be more contextually appropriate for these settings. Countries that have
implemented see-and-treat suggest scale-up is still challenging, which highlights the
importance of addressing implementation in addition to developing new prevention tools.
Despite barriers experienced in practice, results from this dissertation show that
adherence was maintained during scale-up of see-and treat in Botswana and competence
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was sustained over time. More in-depth discussion of adherence and competence results
is provided below.
Adherence
Overall provider adherence was high. 88% of clinical encounters were adherent
to the NCCPP guideline, which is considerably higher than estimates in the literature. A
systematic review, which included 35 guidelines pertaining to a variety of diseases,
reported a wide range of adherence with overall data pointing to relatively low rates
[(Amoakoh-Coleman et al., 2016; Ebben et al., 2013). Adherence ranged from 7.8 to
95% in prehospital settings and 0 to 98% in emergency care settings. Although adherence
was high in this sample, it important to recognize that adherence alone does not guarantee
complete fidelity. Providers can follow the outlined steps of the algorithm, however,
competence (or level of skill) when conducting VIA and cryotherapy is also important to
ensure evidence-based, quality care is reaching patients (Breitenstein et al., 2010; Carroll
et al., 2007). Competence results are discussed in the following section.
Adherence by site
Contrary to the hypothesis, nurses at the scaled-up sites were more adherent to the
NCCPP see-and-treat algorithm than those at the pilot site (90.86% vs. 80.20%),
p<.0001). When controlling for covariates, however, the relationship between adherence
and site was not significant. Scaled-up sites were .9845 times as likely to be adherent.
(p=.2205). In this instance, more expertise and access to resources did not equate to
better adherence. These results suggest that nurses working within the scaled-up sites
could adhere to the guidelines despite increased barriers typically experienced within
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these settings. Although a surprising outcome, there is a multiplicity of possible
explanations for this unexpected result.
One possibility is that nurses at the scaled-up sites found workarounds to deal
with the barriers that they faced in their daily practice. Another factor that was not
initially considered was the role of expert nurses at the pilot site in supervising the
implementation process at scaled-up sites. Each scaled-up site was monitored monthly,
which equates to 5 trips per month for 2-3 days at a time. Oftentimes, the less
experienced nurses remained at the pilot site while the experts made these frequent trips
across the country. Furthermore, the intensity of supervision likely decreased at the pilot
site as it became responsible for managing other sites. It is also possible that nurses at the
pilot site became apathetic toward the guideline recommendations given the 5-year gap
between initial training and scale-up. These nurses may have developed a sense of
mastery over the guideline and willingness to make their own adaptations to it over time.
As suggested by a preliminary exploration into the reasons for nonadherence, some
nurses treated patients that should have been referred. Some nurses may have chosen to
do so out of choice, while others may have needed to so out of necessity to improvise in
scenarios that were not defined in the algorithm. While plausible, these explanations are
merely speculative. Rigorous, in-depth qualitative interviews are needed to further elicit
why the scaled-up sites were more adherent than expected.
Adherence over time
Adherence decreases over time, which is consistent with trends cited in the
literature. A systematic review conducted by Ament et al (Ament et al., 2015) concludes
“professionals’ adherence to a clinical practice guideline in medical care decreased after
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more than 1 year after implementation in about half of the cases”. In consultation with
BUP experts and providers on the ground, there was no significant event to their
recollection that occurred at month 15 and could have contributed to the drastic decline.
There was news that the program funding was ending and that the implementing partner
would be changing from BUP to Jhiepgo, which could have contributed to more
distractions at work and less careful judgements being made. However, I would have
expected to see the same decline in the pilot site with this explanation. It could also be
the general effect that occurs with implementation over time where the vigilance for
adhering to the guideline is heightened in the beginning and wanes over time.
Adherence by patient-level characteristics
Regarding patient-level factors, providers were more likely to adhere to
guidelines when caring for patients who were older, HIV negative, VIA positive, had
more children, and had not reached menopause. Pilot sites had higher proportions of
patient types and characteristics that contributed most towards nonadherence, which
could explain why differences were not significant when controlling for covariates.
Main drivers of nonadherence
Clinical guidelines increase the likelihood that intended outcomes will be
achieved in a safe and evidence-based manner. Ensuring that the program will have the
greatest chance for success is even more pressing for developing countries that are
investing their scarce and limited resources. However, guidelines provide
recommendations and do not mean that other methods are wrong. When seeking to better
understand nonadherence, it is important to assess deviations from the NCCPP algorithm
in terms of potential benefit or harm to patients. Nonadherence should not be a punitive
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measure for providers. Clinicians are the experts and their knowledge and expertise
should always be respected and appreciated. Many innovative and better ways of doing
things are generated from on-the-ground experience and may not be defined within the
algorithm. Guidelines should aid in enhancing their work.
In my analysis of nonadherence, I can only say that behaviors were not aligned
with the protocol and merely speculate as to why and what implications it may have on
patient care and outcomes. There were 3 patient types that were explored to determine
reasons for provider nonadherence: VIA negative HIV negative, VIA negative HIV
unknown, and VIA not performed. For VIA negative patients, nurses often suggested the
incorrect follow-up timeframes or did not recommend follow-up at all. VIA negative
HIV negative patients were frequently recommended for repeat screening in 3 years
rather than 5 years. Asking these low risk patients to come back earlier does not have
adverse implications for patient care. However, it can lead to wasted resources, which is
significant for resource-limited settings like Botswana and can be better allocated to
higher risk patients.
VIA negative HIV unknown patients were typically told to follow-up with
screening in 5 years instead of 3. In regions with high HIV prevalence, guidelines
recommend screening these patients earlier given the association between HIV and
higher risk for developing cervical cancer. Although taught as part of the initial training,
treatment and referral plans for VIA negative HIV unknown patients were not explicitly
stated in the algorithm, which could have contributed to the high nonadherence for this
patient type. Another missing element in the algorithm for VIA negative patients was
cryotherapy for ectropy, which is a valid treatment option for these patients.
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Reassessment and revisions of the algorithm are needed to avoid providers having to rely
on their own judgment when necessary actions are not specified.
Patients from the VIA not performed group had normal cervixes and VIA should
have been performed. Most of these patients were referred or deferred. Unfortunately,
there was not enough information provided in the data set to determine why. The
algorithm notes that nurses should consult when unsure, which is presumably what
occurred. If these patients were eligible for VIA screening, however, time and effort
spent reassessing them at the referral clinic could have been better allocated.
Limitations
Adherence variable. The adherence measure was limited in several ways.
Adherence in this study was determined based on self-reported treatment and referral
actions as documented in the medical chart. However, reported action does not always
equate to actual action taken. Since this data was collected from daily clinical activity,
rather than under surveillance of a research study, I would anticipate low reporting bias.
Additionally, the adherence measure is binary and only indicates whether the nurse
completely followed the algorithm. The variable does not account for differing levels of
adherence, which was not feasible to create with this data set. When designing a future
study, it would be increasingly informative to include a more robust measure that
accounts for degrees of adherence. I would anticipate higher estimates for adherence
with such a measure.
Chart review. There are advantages and limitations for using clinical data
collected through chart review (Vassar & Holzmann, 2013; Worster & Haines, 2004).
Data from medical charts are intended primarily for clinical use so the information
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collected is usually most pertinent to daily practice and can be limited in scope given
time restraints during patient visits. Data is usually collected at the patient-level.
Provider and organizational-level factors are rarely tracked in the patients’ medical chart,
which limited my analysis and what could be controlled for in the regression model (such
as providers’ clinical experience and volume of screenings). Using data from medical
charts is advantageous because it is readily available and less costly. Furthermore, it
shows how events are occurring in the “real-world”, which is the premise of
implementation science.
Missing data. Another potential limitation was missing data. Since this study
used data from day-to-day clinical operations, providers may have been less incentivized
to complete all fields of the intake form. Contrary to expectations, data entry was near
complete with few missing variables that would compromise the analysis. Data clerks,
utilized as part of the implementation strategy, were helpful in assuring completeness of
the data set. The supervisor conducted periodic checks to identify missing values when
data was uploaded onto the spreadsheet. Data clerks would recheck the intake forms in
attempt to retrieve missing data.
Potential confounding. Since randomization was not used in the design of this
evaluation, confounding of unmeasured covariates could have influenced the regression
analysis. Unfortunately, I was unable to obtain information about providers because it
was not collected in the initial data set. Additionally, implementing partners changed
making it difficult to gain access to these providers. Due to severe multicollinearity,
experience also could not be accounted for in the regression analysis. It is an important
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theoretical concept that should be measured differently to avoid collinearity and
considered in future analyses.
Competence
Results from our analysis are consistent with sensitivity and specificity estimates
reported within the literature. Several meta-analyses have been published in recent years
that report pooled sensitivities and specificities for VIA. Regarding sensitivity, VIA has
shown the following ranges: 80% (79%–82%) (Sauvaget et al., 2011), 77% (66%–85%)
(Mustafa et al., 2016), 77% (75%-78%) (Chen et al., 2012), and 73.2% (66.5–80.0%)
(Qiao et al., 2015). Regarding specificity, VIA has shown the following ranges: 92%
(91%–92%) (Sauvaget et al., 2011), 82% (67%–91%) (Mustafa et al., 2016), 87% (88%87%) (Chen et al., 2012), and 86.7% (82.9%–90.4%) (Qiao et al., 2015).
There are also several studies in the literature that report sensitivity and specificity
estimates when comparing nurse VIA assessments to expert physicians during monitoring
and evaluation of their see-and-treat programs. Example countries include: Madagascar
(Catarino et al., 2015; Ricard-Gauthier et al., 2015), Botswana (Quinley et al., 2011a),
Congo (Raifu et al., 2017), South Africa (Firnhaber et al., 2015b), Zambia (Bateman et
al., 2014), Iran (Khodakarami, Farzaneh, Aslani, & Alizadeh, 2011), Brazil (Hillmann
Ede et al., 2013), Ghana (Asgary et al., 2016a), and India (Sherigar, Dalal, Durdi, Pujar,
& Dhumale, 2010). In Botswana specifically, investigators reported sensitivity of 75.3%
(95% CI, 72.5 – 77.8%) and specificity of 98.5% (95% CI, 97.6 – 99.1%) during the pilot
test (Ramogola-Masire et al., 2012). However, we cannot draw fair comparisons
because histology was used when available during the pilot, rather than EDI, to confirm
cases categorized as VIA positive by the nurse. Therefore, the pilot study may be more
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accurate in determining true and false positive rates. Another key difference is that only
women with HIV were eligible to participate in the pilot, which is largely due to the Pink
Ribbon Red Ribbon Initiative (PRRR) funding source. PRRR provides financial and
infrastructural support for cervical and breast cancer services for women with HIV,
understanding their increased risk for developing these diseases. In this study, all women
were eligible to participate despite HIV status, although most participants (67%) are
women with HIV. The high proportion of HIV positivity in this sample is likely due to
newly diagnosed women being largely recruited from the neighboring HIV clinic.
Compared to Pap smear, VIA is more sensitive but less specific. However, the
specificity and sensitivity of VIA depends on the skill with which the procedure is
conducted. As NCCPP continues to be scaled-up nationally, reviewing each picture from
every cervical exam will no longer be feasible and sustainable. The Ministry of Health
will need to determine an alternative way to evaluate VIA competency, which may
involve random sampling of pictures to audit rather than all pictures. Several studies
(Asgary et al., 2016a; Catarino et al., 2015; Parham et al., 2010; Quinley et al., 2011b;
Ricard-Gauthier et al., 2015) used telemedicine to leverage capacity of expert physicians,
which is severely lacking within country, through a virtual platform for consultation
purposes. The audit feedback mechanism of biweekly QA meetings may be integral to
maintaining providers’ competency over time. A comparative effectiveness analysis
would be helpful in determining the frequency with which audit and feedback need to
occur to maintain adequate sensitivity and specificity for VIA exams. Gaffikin et al
(Gaffikin, McGrath, Arbyn, & Blumenthal, 2008) broaches the topic when discussing
verification bias when the percentage of subjects receiving disease verification differs
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according to test result. Less frequent refresher courses or a certification program may be
just as effective but at a much lower cost and reliance on human capacity. A
computerized algorithm that automatically provides audit and feedback has been
suggested. However, a careful cost-benefit analysis would need to be conducted to
ensure the equipment is affordable and can be scaled-up for wide spread use.
In practice, the pilot site was not always able to biweekly QA meetings and went
for longer periods of time. For VIA positive patients, there were instances where the
patient had already been seen at the referral clinic and had colposcopy results before their
picture was reviewed at the QA meetings.
Limitations
Competence measure. In order to calculate sensitivity and specificity, multiple
VIA results (positive, inadequate, uncertain, suspicious of cancer) were accounted for in
the abnormal category, which lost some degree of information in the analysis.
Additionally, creating the VIA physician result required interpretation of handwritten
comments in the QA book. However, discrepancies were resolved through consensus
and consultation with clinical experts in Botswana.
Enhanced digital imaging. Poor image quality can threaten the validity of
physicians’ cervical assessments when using EDI. Image quality is dependent on a good
light source and an unobstructed view of the cervix. Nurses were trained on how to
properly use the digital cameras and assess image quality (Quinley et al., 2011a;
Ramogola-Masire et al., 2012). EDI may not be as objective as histology in validating
VIA results, but it is a cost effective and reliable method. Although 3 different
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physicians evaluated pictures during the QA meetings, unanimous consensus had to be
achieved or the patient was recalled when discrepancies occurred.
Conclusion
The overarching goal of this dissertation was to better understand the
implementation of cervical cancer prevention programs in resource-limited settings.
Using Botswana as a case example, this research accomplished that goal by
comprehensively evaluating providers’ fidelity to the NCCPP see-and-treat algorithms.
Study design limits the conclusions that can be drawn regarding causal relationships.
Future comparative effectiveness trials are needed to definitively determine the
effectiveness of implementation strategies used in the scale-up of see-and-treat, such as
audit and feedback through quality assurance meetings and ongoing consultation visits to
scaled-up sites. However, results from this analysis suggest that there are successful
elements of the NCCPP scale-up strategy. Adherence was maintained during scale-up
and competency was sustained over time.
Although a resource-limited setting, Botswana has unique characteristics of its
female population that may affect the application of these findings to scale-up in similar
contexts. Botswana has a relatively small population of around 2 million people, which
may make it easier to achieve adequate program coverage. Also, Botswana was one of
the poorest countries in Africa before the recent discovery of diamonds. However,
Botswana is now considered an upper-middle income country and has the fastest rate of
economic growth in the world. Even though the country’s economy has improved,
Botswana still faces infrastructural and organizational limitations and high income
inequality. Furthermore, Botswana has a high HIV prevalence rate, which is the third
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highest in the world. HIV, which causes the body to become immunocompromised, is
associated with an increased risk for developing cervical cancer. Therefore, Botswana
could potentially be dealing with higher proportions of patients with abnormal VIA
results, which also provides a potential explanation for high rates of referral in this
population. Rates of VIA positivity and referral may be higher in Botswana compared
with other countries making different implications for adherence/competency and
generalizability of these results.
Practice. Through this study, I have collected the quantitative data to identify
problematic segments of the NCCPP see-and-treat algorithm and plan to conduct future
qualitative interviews to further elicit how and why providers experience implementation
challenges in their daily practice. In their upcoming 5-year evaluation, Botswana’s
Ministry of Health will be able to utilize these results to modify the algorithm and/or
develop strategies to improve the implementation process moving forward. The formative
work from this research can also inform the future development and testing of an
evidence-based fidelity instrument to facilitate the ongoing monitoring and evaluation of
NCCPP. Currently, there is no standard method for evaluating NCCPP and no valid,
reliable measure exists within the literature. Cervical cancer is amongst the most
prevalent cancers not only for women in Botswana but also in the entire sub-Saharan
region. Therefore, this research will also be beneficial for other countries implementing
similar national prevention programming.
Research. As a newly developed field, implementation science calls for increased
efforts in building frameworks, outcomes, measures, etc. to advance the science. This
research helps to advance conceptualization and measurement of fidelity. Within the
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literature, fidelity has frequently been measured using self-report, direct observation, or
audio/video recording (Breitenstein et al., 2010). Typically, researchers will use a
checklist to determine whether key components of the intervention have been addressed.
Less commonly, fidelity is assessed through chart review and for a set of sequential steps
of an evidence-based guideline, which is an innovative method used in this study. As
understudied concepts, this paper also progresses the field by providing baseline
estimates for adherence and competence.
Policy. The implementation story of see-and-treat in Botswana is a very
interesting example of how a country with limited resources has to adapt to the rapidly
changing landscape of prevention as new technologies are introduced into the field. It
requires finding the balance between efficacy and practicality while also considering the
resource limitations and implementation barriers of these settings. Botswana’s MOH will
be adding HPV vaccination and HPV self-sampling as part of the new 2017-2022
NCCPP strategy. Ensuring adequate implementation and scale-up of see-and-treat is
particularly important because it will remain an integral part of the algorithm despite
future planned roll out of HPV DNA self-sampling. When VIA was introduced, Pap
smear was no longer the primary screening method but was still used as a secondary
screening for patients with VIA inadequate results. In similar ways, HPV self-sampling
will become the primary, triage method of prevention but HPV positive patients will still
need further screening with VIA or Pap. Therefore, successful scale-up of see-and-treat is
essential for creating a solid foundation for implementing HPV DNA self-sampling, the
future of cervical cancer prevention.
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Statistical Appendix
The following appendix provides further explanation for the statistical analysis
conducted for Aim 2 of this study. Details are provided regarding generalized estimating
equations, purposeful variable selection, and odds ratios vs. risk ratios.
The chi squared X2 statistic is quite limited regarding inferences that can be drawn
about the relationship between adherence and site, especially since randomization was
not used in collecting the data. Random assignment creates groups that are similar
regarding known and unknown confounders. In the absence of randomization, there may
be considerable baseline differences between the pilot and scaled-up sites that are
confounding the observed relationship between adherence and site. Regression analysis
is a useful statistical tool that can be used to control for measured covariates, improving
our confidence and ability to make inferences about adherence and site. Therefore,
multiple regression analysis was also used to confirm whether site is significantly
associated with adherence after controlling for measured covariates.
GEE is typically used when analyzing longitudinal or clustered data. In multiple
regression analysis, assumptions must be made that observations are independent.
However, we assume in the context of this study that data are correlated and observations
from the same provider are more alike than observations between two different providers.
Risks of not accounting for correlation in clustered data include potential for
underestimated standard errors and exaggerated strength of association/statistical
significance. GEE is further advantageous because it is robust to misspecification of the
correlation/covariance structure and provides consistent parameter estimates.
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GENMOD is the procedure used in SAS to conduct GEE. Even if correlation
values remain small/low when the model is run, statisticians still advise using GEE if
there is a theoretical basis to suggest that the data are correlated. The procedure requires
specification of variables (dependent, independent, clustering), link function, distribution,
and correlation structure.
● Variables
The dependent variable, or outcome variable, was adherence (PILOT).
The primary explanatory variable was site (PILOT). The covariates that
were tested in the model as potential significant confounders included:
AGE, PARA, SEX_AGE, HIV, SMOKE, MENO, CC_SRN, DATE, EXPER.
The clustering variable was clinician (CL_NAME).

● Link function/Distribution
Initially, logistic regression (link=logit, dist=bin) was specified as the link
function to determine odds ratios (ORs). However, consulting statisticians
advised that relative risk/risk ratios (RRs) can be more appropriate when
prevalence is common (typically greater than or equal 10%). ORs
adequately approximate RRs when prevalence is low but can become
increasingly inaccurate with higher prevalence. Since overall prevalence
in our sample was 11.61% and close to the cutoff, we decided to also
estimate RR. RR can be approximated using the adjusted ORs obtained
with a simplified equation suggested in [Zhan 1998].

RR can also be

derived directly through log-binomial regression (link=log, dist=bin),
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which is often the preferred method by statisticians. ORs did not provide
good estimates for RRs in this sample. Results for ORs calculated from
logistic regression are shown at the end of this appendix. Therefore, RR
were reported in this study.
● Correlation structure
As specified earlier, GEE modelling is robust to misspecification of
correlation structure. The literature suggests starting with exchangeable
unless otherwise indicated/thought based on theory. QIC criteria were
compared between exchangeable (CS) and autoregressive AR(1) for
sensitivity purposes. Exchangeable consistently performed better and was
used in the analysis.
According to Hosmer et al, the goal for regression analysis is to “find the best
fitting and most parsimonious, clinically interpretable model to describe the relationship
between an outcome (depend or response) variable and a set of independent (predictor or
explanatory) variables” [Hosmer]. The importance of fitting the most parsimonious
model is to eliminate any insignificant covariates that may be creating inaccurate
parameter estimates. Multiple regression modelling in this study was conducted using
methods for purposeful covariate selection cited in Hosmer, Lemeshow, and Sturdivant’s
Third Edition of Applied Logistic Regression. Hosmer is among a limited number of
sources that provide concrete advice and examples for modeling correlated data with
GEE. Purposeful selection of covariates was used in this analysis and involves the
following steps:
•

Identify significant independent variables
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Each independent variable was assessed through univariable analysis (with
the dependent variable, adherence). The purpose of this step is to elicit
candidates for the model that are significantly associated with the
outcome. Variables with p<.25 and/or known clinical importance meet
criteria for inclusion in the model.
●

Fit a multiple regression model with significant variables from Step 1
The variables identified in Step 1 that met inclusion were fit in the initial
GEE model. Significance of each variable was reassessed once in the
model to see if relationships change in the presence of other variables.
Variables with p<.10 remained in the model. Starting with the highest p
value, variables with p>.10 were deleted from the model one-by-one.
After a variable was deleted, coefficients of the remaining variables were
assessed. Any change in coefficients >20% indicated that the deleted
variable was important to the model in terms of adjustment and was added
back.

● Test non-significant variables in that model that were excluded in Step 1
Variables that did not meet inclusion criteria in Step 1 were added one-byone to the reduced model in Step 2. This helped to identify variables that
are not significantly related to the outcome by themselves but do in the
presence of other variables. Variables with p<.01 were kept in the model.
● Check for interactions
Interaction terms are used when the effect of the outcome is not constant
across categories of categorical variable. Within this method, theoretically
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plausible interaction terms are added to the preliminary main effects
model from Step 3. Each interaction terms are added one by one and
maintained in the model if p<.1. The resulting model is referred to as the
main effects model. For the purposes of this study, we only added
interactions between site and other significant covariates since we are
centrally concerned with how patient characteristic associated differently
at pilot and scaled up sites.
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Results from Univariate Analysis – Estimating Adherence to NCCPP See-and-Treat
Algorithms Using Logistic Regression Modeled with Generalized Estimating Equations
(N=6580)
Variable
PILOT
Scaled-up site
Pilot site
AGE
Patient age
PARA
# of children
SEX_AGE
Age of debut
MENO
Yes
No
SMOKE
Yes
No
HIV
Negative
Positive
Unknown
CC_SRN
Yes
No
Unknown
PT
Normal: VIA neg
Normal: VIA pos
Normal: VIA other
Normal: VIA not p
Abnormal cervix
DATE
Months from start
date (Jan 2014)
DATESQ

Unadjus
ted OR

95%
CI
Lower

95%
CI
Upper

Unadjust
ed RR

95%
CI
Lower

95%
CI
Upper

1.4472
ref

0.9207

2.2746

1.3295

0.9354

1.8162

1.0197

1.0088

1.0307

1.0157

1.0071

1.0244

1.0736

1.0093

1.1418

1.0582

1.0075

1.1106

.1092
.0004
.0241
.0933
0.9853

0.9685

1.0025

.9882

0.9746

1.0020

0.7091
ref

0.4413

1.1396

.7525

0.4962

1.1090

.1556

.9347
1.0276
ref

0.5360

1.9701

1.0220

0.5902

1.6527

4.9392
3.5633
ref

2.9064
2.1178

8.3947
5.9954

2.7749
2.3637

2.1099
1.7340

3.4067
3.0142

1.0152
0.9206
ref

0.2141
0.1938

4.8143
4.3732

1.0122
.9353

0.2536
0.2306

2.7428
2.6220

<.0001

.2364

<.0001
1.0993
2.4090

0.6883
1.2685

1.7561
4.5754

1.0781
1.8835

0.7335
1.2044

1.5274
2.6789

0.7385
0.0949
ref

0.3585
0.0543

1.5209
0.1658

0.7788
0.1156

0.4107
0.0669

1.3787
0.1986

0.9987

0.9595

1.0422

0.9673

1.0335

.9525
.9990
.6720
0.9995

EXPER
Months adjusted
between sites
EXPERSQ

Wald

0.9974

1.0017

.9996

0.9979

1.0014
.1815

0.9940

0.9852

1.0028

0.9881

1.0022

0.9998

1.0000

.9952
.1823
0.9999

0.9998

1.0000

.9999
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Results from Multiple Regression Analysis – Estimating Adherence to NCCPP See-andTreat Algorithms Using Logistic Regression Modeled with Generalized Estimating
Equations (N=6580)
Variable

Adjuste
d OR

95%
CI
Lower

95% CI
Upper

Adjuste
d RR

95%
CI
Lower

95%
CI
Upper

Wald

.4252

0.2235

0.8090

.4798

0.2641

0.8408

2.1673
ref

1.4120
.

3.3264
.

1.7604
.

1.3055
.

2.2774
.

1.0271

1.0105

1.0440

1.0216

1.0084

1.0350

0.6037
ref

0.3411
.

1.0688
.

.6551
.

0.3922
.

1.0544
.

6.3230
4.3899
ref

3.9725
2.5659
.

10.0644
7.5105
.

3.0785
2.6268
.

2.5007
1.9586
.

3.6012
3.2810
.

1.1794
2.7363

0.7319
1.2742

1.9005
5.8756

1.1389
2.0362

0.7729
1.2086

1.6129
2.9896

.0092
.0004
.0004
.
.0013
.0013
.0833
.0833
.
<.0001
<.0001
<.0001
.
<.0001
0.4979
0.0098

0.6911
0.0700
ref

0.3020
0.0398
.

1.5817
0.1232
.

0.7362
0.0858
.

0.3504
0.0491
.

1.4183
0.1491
.

0.3818
<.0001
.

INTERCEPT
PILOT
Scaled-up site
Pilot site
AGE
Patient age
MENO
Yes
No
HIV
Negative
Positive
Unknown
PT
Normal: VIA neg
Normal: VIA pos
Normal: VIA oth
Normal: VIA not
Abnormal cervix
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